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This research focuses on developing new and computationally efficient statistical learning methods
for multicategory classification and personalized medical decision making. Motivated by the challenge
of multicategory classification problems, and the computational efficiency and theoretical properties
of support vector machines (SVM), a novel learning algorithm is proposed. The method is then
adapted to estimating multicategory individualized treatment rules by connecting with outcome
weighted learning (Zhao et al., 2012). At last, an application to Electronic Health Record data is
explored.
The proposed algorithm, forward-backward SVM (FB-SVM) is based on a sequential binary
classification algorithm and relies on support vector machines for each binary classification and
utilizes only feasible data in each step. Therefore, the method guarantees convergence and entails light
computational burden. More importantly, we prove the theoretical property of Fisher consistency of
the classification rule derived from the FB-SVM, which is not guaranteed by existing algorithms. We
also obtain the risk bound for the predicted misclassification rate. We conduct extensive simulation
and application studies, using popular benchmarking data and data from a newly completed real-
world study, to demonstrate that the proposed method has superior performance, in terms of low
misclassification rates and significantly improved computational speed when compared to existing
methods.
Furthermore, we generalize the proposed FB-SVM with outcome weighted learning to estimate
optimal individualized treatment rule (ITR) with multiple options of treatment, namely sequential
outcome-weighted learning (SOM). Specifically, we solve a multicategory treatment selection problem
via sequential weighted support vector machines. Theoretically, we show that the resulting ITR is
Fisher consistent. We demonstrate the performance of proposed method with extensive simulations.
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An application to a three-arm randomized trial of treating major depressive disorder shows that an
individualized treatment strategy tailored to individual characteristics such as patients’ expectancy
of treatment efficacy and baseline depression severity reduces depressive symptoms more than
non-personalized treatment strategies.
Finally, we discuss how the proposed SOM learning can be used to estimate optimal ITRs with
safety concerns in high dimensional electronic health record data, which are collected from the
Indiana Network for Patient Care database with patients’ adverse reaction records who have taken
statin medicine. We adopt sampling techniques, inverse probability weighting, propensity score
adjustment, and variable clustering along with SOM learning in our analysis. Considering patients’
electronic records of demographics and medical history, we are able to recommend the best statin
drug which has the lowest risk to cause myopathy or rhabdomyolysis using SOM learning.
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CHAPTER 1: INTRODUCTION
Multicategory classification is a fundamental and challenging problem in machine learning
and empirical application. While binary classification methods are well-developed, multicategory
classification is a heavily debated research topic in the machine learning literature. In addition, a
multicategory classification learning method can be well applied to estimate individualized treatment
rules in trials with more than two treatment arms, which is also not sufficiently developed in existing
literatures. Motivated by the need to create a computationally efficient method of consistent learning
rules, we develop statistical learning methods for multicategory classification and estimating optimal
personalized treatment rules.
In the first topic (see Chapter 2), we propose a new and computationally efficient learning
algorithm, namely, forward-backward support vector machine (FB-SVM), to perform multicategory
learning. The new method is based on a sequential binary classification algorithm: we first classify
a target class by excluding the possibility of labeling as any other classes using a forward step of
sequential SVM; we then exclude already classified classes and repeat the same procedure for the
remaining classes in a backward step. The proposed algorithm relies on support vector machines
for each binary classification and utilizes only feasible data in each step; therefore, the method
guarantees convergence and entails light computational burden. More importantly, we prove the
theoretical property of Fisher consistency of the classification rule derived from the FB-SVM, which
is not guaranteed by existing algorithms. Furthermore, we obtain the risk bound for the predicted
misclassification rate. We conduct extensive simulation and application studies, using popular
benchmarking data and data from a newly completed real-world study, to demonstrate that the
proposed method has superior performance, in terms of low misclassification rates and significantly
improved computational speed when compared to existing methods.
Personalized medicine has received increasing interest among clinicians and statisticians. Par-
ticularly, one aspect of personalized medicine is to consider an individualized treatment strategy
based on an individual’s characteristics that leads to the greatest benefit in the patient population.
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Recently, powerful machine learning methods have been proposed to estimate optimal individualized
treatment rule (ITR) but are only restricted to the situation with only two treatments. When
multiple treatment options are being considered, which is often the case in many studies, these
methods have to handle complex treatment-treatment interactions by transforming multicategory
treatment selection into multiple binary treatment selections. However, combining conclusions from
multiple binary treatment selection is not straightforward and it may lead to inconsistent decision
rules. There is a lack of literature on using multicategory learning to estimate optimal ITR. In the
second topic (see Chapter 3), we fill this gap by proposing a novel and efficient method to generalize
outcome weighted learning to multi-treatment settings. Theoretically, we show that the resulting
ITR is Fisher consistent. We demonstrate the performance of the proposed method with extensive
simulations. An application to a three-arm randomized trial of treating major depressive disorder
shows that an individualized treatment strategy tailored to individual characteristics such as patients’
expectancy of treatment efficacy and baseline depression severity reduces depressive symptoms more
than non-personalized treatment strategies.
In the third topic (see Chapter 4), we discuss how the proposed learning algorithm can be used
to estimate optimal ITRs with safety concerns in high dimensional data, which are collected from
the Indiana Network for Patient Care database with patients’ adverse reaction records who have
taken statin medicine. In this work of observational data. we adopt sampling techniques, inverse
probability weighting, propensity score adjustment, and variable clustering along with SOM learning
to take care of potential bias and confounding, large computational cost, and sparsity. Tailored to
patients’ demographics and medical history, SOM learning is able to recommend the best statin
drug which has the lowest risk to cause myopathy or rhabdomyolysis. Results of Q-learning and
non-individualized treatment rules are also explored.
Chapters 2 to 4 each contains an introduction and relevant literature review, an explication
of the problem, the proposed methods followed by theoretical properties, numerical examples and
conclusions. Chapter 5 represents ideas for future research.
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CHAPTER 2: MULTICATEGORY CLASSIFICATION VIA
FORWARD-BACKWARD SVM
2.1 Introduction
Multicategory classification is a fundamental and challenging problem in machine learning and
empirical application. For instance, cancer is staged into more than two levels of categorization. An
accurate classification of a patient’s cancer stage is crucial for prognosis and the choice of an effective
treatment. While binary classification methods are well-developed, multicategory classification is a
heavily debated research topic in the machine learning literature.
The existing methods for multicategory classification can be divided into two general approaches.
The first approach is to convert multicategory classification problems into sequential binary problems
such as one-versus-all and one-versus-one methods (Dietterich and Bakiri, 1995; Kreßel, 1999; Allwein
et al., 2001). These methods are relatively simple to implement because all work is accomplished
using existing off-the-shelf techniques for binary classification problems, although the one-versus-one
approach requires significantly more computational time than the one-versus-all approach (Hsu and
Lin, 2002; Rifkin and Klautau, 2004). However, although easy to implement, these methods suffer
from the risk of inconsistent results because an input sample may be assigned to multiple classes
depending on the choice of binary classification. Thus, these methods do not satisfy the Fisher
consistency property, and their misclassification error rates cannot achieve the optimal Bayesian
error rate. Additionally, with the one-versus-all approach, the training set is imbalanced because
there are many more subjects in the remaining classes than in the targeted class (Bishop, 2006).
The second approach to learning algorithms for multicategory classification is to form a single
loss function for minimization so as to obtain a simultaneous multicategory objective function
(Vapnik and Vapnik, 1998; Weston et al., 1999; Bredensteiner and Bennett, 1999; Crammer and
Singer, 2002; Lee et al., 2004; Liu and Shen, 2006; Liu and Yuan, 2011). The key question is
how to choose a sensible multicategory loss function. To better understand each loss function, we
introduce a few notations. Let f = (f1, f2, ..., fk) be a vector of decision functions, where each
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component represents one of k classes. Suppose an input x belongs to class y, then the loss function
used in Vapnik and Vapnik (1998), Weston et al. (1999) and Bredensteiner and Bennett (1999) is∑
j 6=y[1− (fy(x)− fj(x))]+, which pays a certain penalty when fy(x)− fj(x) < 2. The authors in
Lee et al. (2004) and Liu (2007) have shown that the loss may be Fisher inconsistent by providing
a special case for 3-category classification problems. When all probabilities of being assigned to
one of the three classes are less than 1/2, the loss is inconsistent if the second largest probability is
greater or equal to 1/3. The loss function in Crammer and Singer (2002) and Liu and Shen (2006)
has a similar formulation, [1−minj(fy(x)− fj(x))]+. The difference is that this loss function pays a
penalty only for the smallest difference between the targeted class and the other classes. This loss
function is not convex and is Fisher consistent only when there is a dominating class, which is not
guaranteed for multicategory classification (Zhang, 2004; Tewari and Bartlett, 2007; Liu, 2007). In
Crammer and Singer (2002), a dual decomposition algorithm for the Lagrangian dual with kernel
product was developed to solve the quadratic programming problem. Liu and Shen (2006) applied
the difference convex decomposition to address the problem of non-convex minimization and provided
the convergence rate. The loss function proposed by Lee et al. (2004) is
∑
j 6=y[1 + fj(x)]+, which is a
consistent generalization of hinge loss. The authors derived a Lagrangian dual but did not provide the
decomposition algorithm. Despite the non-convexity of the loss function, another drawback of Lee,
Lin, and Wahba’s (Lee et al., 2004) is that the tuning criterion based on generalized cross-validation
tends to over-estimate the tuning parameter, which may result in inaccurate classification. Liu and
Yuan (2011) proposed reinforced hinge loss function γ[(k − 1)− fy(x)] + (1− γ)
∑
j 6=y[1 + fj(x)]+,
which is a convex combination of Lee, Lin, and Wahba’s loss function and a direct generalized
hinge loss. The authors stated that the loss function is consistent when γ ≤ 1/2 or under certain
circumstances when γ > 1/2. The algorithm contains both quadratic and linear programming
problems with respect to each part of the loss function.
In this paper, we propose a novel algorithm – forward-backward support vector machine (FB-SVM)
– to break a multicategory classification problem into sequential binary classifications in a way that
takes advantage of computational efficiency and also allows consistent theoretical properties. For
each binary step in our algorithm, we use a weighted support vector machine (SVM) for classification
because the theoretical properties of binary SVMs are well established and flexible to allow for the
incorporation of powerful kernel learning (Cristianini and Shawe-Taylor, 2000; Friedman et al., 2001;
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Schölkopf and Smola, 2002; Lin, 2004). We first classify a target class by excluding the possibility
of labeling as any other classes using a forward step of sequential SVMs; we then exclude already
classified classes and repeat the same learning approach for the remaining classes using a backward
step. By carefully choosing weights in each SVM step and constructing the final classification rules
to combine the decision functions from all SVM steps, we show that the derived rule from FB-SVM
is Fisher consistent, and we obtain the risk bound for the predicted misclassification rate. Moreover,
we demonstrate through extensive simulation and application studies that FB-SVM has superior
performance in terms of low misclassification rates and significantly improved computational speed,
in comparison to existing methods.
The paper is structured as follows. Section 2 introduces the concept of FB-SVM using a 3-
category classification problem, with the general algorithm for more than 3 categories provided at
the end of the section. In Section 3, we provide the theoretical properties of FB-SVM, including
Fisher consistency and the convergence rate of the predicted misclassification rate. Sections 4 and 5
present simulations and applications for illustration. Finally, a discussion and concluding remarks
are provided in Section 6. Proofs of the theoretical results are presented in the Appendix.
2.2 Methodology
2.2.1 An illustration of FB-SVM for 3-category learning
We use a 3-category problem to introduce FB-SVM. Suppose we have a training dataset with n
pairs of predictors and outcomes {xi, yi}, i = 1, ..., n, where xi is the d-dimensional input, and yi is
the corresponding class label for each sample, taking value 1, 2, or 3.
First, use class 3 as the target and obtain a decision function for this class. The idea is to
produce some rules in order to eliminate any possibility that a sample will be classified with label
1 or 2. For this purpose, we first obtain a rule to classify label 1 versus {2, 3}. Because this is a
classification of one versus two classes, subjects with label 1 must be weighted twice as much as
subjects labeled 2 or 3. After we obtain such a rule, we next consider the subjects with labels 2 or
3 who are not classified with label 1. Using these data, we then perform another classification to
discriminate between classes 2 and 3. Hence, any subject who is not classified with label 1 or label 2
will be classified with label 3. The choice of beginning with label 1 is arbitrary, and a mislabeling
can potentially affect the second classification between classes 2 and 3. To remedy this, we can start
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from label 2 by first discriminating between classes 2 and {1, 3} and then discriminating between
classes {1, 3} using another sequential SVM. Combining the above, we classify a subject with label 3
if either of the two sequential classification rules classifies this subject with label 3. Because this
ordered classification is based on sequential SVMs, where each step depends on the rules obtained in
the previous steps, we term this procedure a forward SVM.
Next, we aim to improve the rule for classifying a subject with labels 2 or 1. This can be carried
out by eliminating subjects with label 3 and those who are already classified as label 3. Thus, the
remaining data consist only of subjects with labels 1 or 2 who cannot be classified with label 3. We
then perform a simple SVM to discriminate between classes 1 and 2 using the reduced data. Because
of this backward elimination step, we term this procedure a backward SVM.
In summary, we collectively obtain a classification rule via a forward weighted SVM to construct a
decision rule for class 3. We then eliminate infeasible data using a backward step and further construct
a decision rule to distinguish the remaining two classes using a restricted sample. Generalization to
any number of multiple categories is provided in the next section.
2.2.2 FB-SVM for general multicategory learning
Now, we extend the 3-category problem to the k-category, where k ≥ 3. The training dataset
consists of n pairs of predictors and outcomes {xi, yi}, i = 1, ..., n, where xi ∈ Rd is feature variables
for subject i, and yi ∈ {1, 2, ..., k} is the class label. As described previously, the main idea of
FB-SVM is to perform a sequence of binary SVMs in order to exclude any possibility of classification
into the class other than a pre-specified target class (forward SVM) and then perform backward
elimination to exclude already determined classes and identify decision rules for the remaining classes
(backward SVM). We describe the details of the method for the k-category below.
We first order the classes based on the descending order of prevalences. Specifically, we first
learn the most prevalent class, then the second prevalent class, and then the rest. Without loss of
generality, we assume that the order of the labels is k, k− 1, k− 2, ..., 1. To learn a classification rule
for class label k, we consider all permutations of labels {1, 2, ..., k− 1}. For the jth permutation, say
{j1, ..., jk−1}, we conduct a sequence of (k−1) binary classifications. In the first binary classification,
we learn a decision rule by comparing label j1 versus the remaining labels, i.e., j2, j3, ..., jk−1, jk = k.
In the second binary classification, we make use of samples that are not in class j1 and not classified
with label j1 to learn a binary classification decision rule by comparing label j2 versus the remaining
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labels, i.e., j3, ...., jk−1, jk = k. We then continue this binary classification procedure so that at the
lth step, we use samples that are not in the previously considered classes and not classified with any
of the previous labels to learn a binary decision rule by comparing label jl versus jl+1, ..., jk = k. In
the final step, i.e., the (k − 1)th step, the binary classification compares label jk−1 vs jk = k.
Because we are comparing one class versus the remaining classes at each step, the binary
classification should be weighed to balance the classes in order to account for the fact that one class
is compared to multiple classes. Specifically, at the lth step, we weight class jl by (k − l)/(k − l + 1)
and weight the combined remaining classes by 1/(k− l+ 1). We will show that this weighting scheme
ensures Fisher consistency of the proposed method.
Mathematically, we can express the above forward SVM algorithm as follows. Consider the jth
permutation {j1, ..., jk−1}, and let jk = k.
1. At step 1, define zij1 = 1− 2I{yi 6= j1}, and estimate a decision rule sign(f̂j1(x)) using a weighted








I(zij1 = 1)[1− f(xi)]+ +
1
k
I(zij1 = −1)[1 + f(xi)]+
}
+λnj1‖f‖2,
where x+ = max(x, 0) is the hinge loss, ‖ · ‖ denotes a semi-norm for f , and λnj1 is a tuning
parameter. In particular, if we consider a linear decision rule, i.e., f(x) = βTx + β0, ‖f‖ is chosen
as the Euclidean norm of β; if a nonlinear decision rule is desired, f is chosen from a reproduced
kernel Hilbert space, and ‖f‖ is the corresponding norm in that space.
2. At step 2, we restrict the training data to those samples whose labels are not j1 and are not
classified with j1 from the previous step. Thus, we estimate a decision rule sign(f̂j2(x)) using a













I(zij2 = 1)[1− f(xi)]+ +
1
k − 1




where zij2 = 1− 2I(yi 6= j2), and λnj2 is a tuning parameter.












k − l + 1
I(zijl = 1)[1− f(xi)]+ +
1
k − l + 1




where zijl = 1− 2(yi 6= jl). Note that we use weight (k − 1)/(k − l + 1) vs 1/(k − l + 1) to account
for the classification of one class versus multiple classes.
Based on this sequence of the forward SVMs, we conclude that a subject will be classified into
class k, the pre-determined target class, if
f̂j1(x) < 0, f̂j2(x) < 0, ... f̂j,k−1(x) < 0.
For notation simplification, we denote D̂kj (x) = 1 if the above conditions hold and let D̂kj (x) = −1
otherwise.
The choice of this sequential binary classification is based on the jth permutation (j1, ..., jk−1),
and so it may not exhaust the correct classification with label k due to this specific choice. Thus, we
repeat the above forward SVM for any possible permutation to obtain D̂kj (x) for all j = 1, ...., (k−1)!.
Consequently, our final classification rule to classify a subject with label k if and only if D̂kj (x) = 1






then we classify a subject with label k if and only if D̂k(x) = 1.
Next, we aim to construct a decision rule for class label (k−1). We adopt a backward elimination
procedure. Delete the samples whose class labels are not k and are not classified with label k in
the previous step. In other words, we restrict the training dataset to samples with yi 6= k and
Dk(xi) = −1. Because the data consist of only (k− 1) class labels, we use the same forward SVM as
before but now set class label (k − 1) as the final class in the sequential classification algorithm. By
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this procedure, we obtain a decision rule at each step of each permutation of {1, 2, .., k− 2}, denoted
by D̂(k−1)j (x), j = 1, ..., (k − 2)!. Consequently, we will classify a subject with label (k − 1) if and






We continue this backward elimination and forward SVM to obtain D̂(k−2)(x), ..., D̂1(x) in turn.
Our final classification rule from FB-SVM is
D̂(x) =

k D̂(k)(x) = 1
k − 1 D̂(k)(x) = −1, D̂(k−1)(x) = 1
...
...
2 D̂(k)(x) = −1, . . . , D̂(3)(x) = −1, D̂(2)(x) = 1
1 D̂(k)(x) = −1, . . . , D̂(3)(x) = −1, D̂(2)(x) = −1.
(2.1)
Our algorithm for k-category FB-SVM can be summarized as follows:
Backward loop with target class s ∈ {k, ..., 1}:
Inner loop: for each permutation of the remaining classes except the previously
classified classes and target class s , we perform a sequence of forward SVMs with
weights to learn D̂sj (x) (j = 1, ..., (s− 1)!).
We collect all rules to obtain D̂s(x) = max(s−1)!j=1 D̂sj (x).
After eliminating all samples with true labels of already classified classes or are classified
with any of the previous labels, go to the backward loop step.
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We note that FB-SVM requires a total of
k∑
l=1
(l − 1)× (l − 1)! = k!− 1
weighted binary SVM classifications. However, because of the sequential data elimination, the
size of the input dataset keeps decreasing in a proportional fashion. Therefore, FB-SVM can be
computationally efficient due to the fast implementation of SVM and reduced data sizes. In our
numeric implementation, SVM at each step is implemented in MATLAB with package LIBSVM
(Chang and Lin, 2011).
2.3 Theoretical Properties
In this section, we provide important theoretical properties for the proposed FB-SVM, including
its Fisher consistency and convergence rate in terms of n. Zhang (2004); Tewari and Bartlett (2007);
Liu (2007) have discussed Fisher consistency for several existing convex, margin-based multicategory
loss functions. For multicategory hinge losses, geometric illustrations of Fisher consistency have been
provided by Hill and Doucet (2007). First, we prove that the proposed FB-SVM is Fisher consistent.
That is, when the sample size is infinity, the derived classification rule is the same as the Bayesian
rule given as
argmaxkl=1Pl(x),
where Pl(x) = P (Y = l|X = x). We introduce some notation for the classification rule from
FB-SVM when n = ∞. Let f∗jl(x) be the counterpart of f̂jl(x) in the FB-SVM procedure when
n =∞ and the tuning parameters are zeros. Similarly, we let D∗lj (x) and D∗l(x) be the corresponding




k D∗(k)(X) = 1
k − 1 D∗(k)(X) = −1,D∗(k−1)(X) = 1
...
...
2 D∗(k)(X) = −1, . . . ,D∗(3)(X) = −1,D∗(2)(X) = 1
1 D∗(k)(X) = −1, . . . , D∗(3)(X) = −1,D∗(2)(X) = −1.
(2.2)
Theorem 2.1. FB-SVM classification rule D∗(X) is Fisher consistent. That is, D∗(x) = l if and
only if Pl(x) = maxkh=1 Ph(x) for l = 1, ..., k.
Next, we provide the convergence of the predicted misclassification rate from the Bayes error
under some additional conditions for Pl(x), l = 1, ..., k, assuming that the functional spaces for fjl
are from a reproducing kernal Hilbert space (RKHS) with Gaussian kernel and bandwidth 1/σn.
Specifically, we assume:
Condition 2.1. There exists a positive constant δ0 such that 0 < δ0 < Pl(x) < 1− δ0 < 1 for any
l = 1, ..., k and x in the domain of X.
Condition 2.2. (Geometric noise conditions) There exist q, β > 0, and a constant c such that for
any permutation of {1, ..., k}, denoted by {j1, ..., jk}, it holds that for any s > l,
P
{∣∣∣ηl(X)− 1
s− l + 1
∣∣∣ < t} ≤ (ct)q, l = 1, ..., k,
where ηl(x) = P (Y = jl





s− l + 1
∣∣∣] ≤ ctβ,
where ∆(X) denotes the distance from X to set {x : ηl(x) = 1/(s− l + 1)} .
Condition 2.3. The distribution of X satisfies tail component condition P (|X| ≥ r) ≤ cr−τ for
some τ ∈ (0,∞].
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Condition 2.4. There exists λn such that λn → 0 and nλn →∞. Moreover, all tuning parameters
λnj satisfy M−1λn ≤ λnj ≤Mλn. We further assume σn →∞.
Remark 2.1. In condition (2.2), the constants q and β are called noise exponent and marginal noise
exponent, respectively. They are used to characterize the data distribution near the classification
boundary when we classify category jl versus {jl+1, ..., jk}. In particular, when the boundary is fully
separable, that is |ηl − 1/(s− l + 1)| > δ0 for a constant δ0, these conditions hold for q = β = ∞.
In condition (2.3), τ describes the decay of the distribution of X. Obviously, when X is bounded,
τ =∞. Condition (2.4) assumes the choice of tuning parameter and bandwidth in RKHS. We choose
this simplification for convenience, although we can allow the tuning parameter and bandwidth to be
different for each classification in the proposed method.
Under conditions (2.1)-(2.4), we show that the following theorem holds.
Theorem 2.2. Under conditions (C.1)-(C.4), for any ε0 > 0, d/(d + τ) < p ≤ 2, there exists a
constant C such that for any ε > 1, with probability at least 1− e−ε,




















Remark 2.2. Suppose that X is bounded such that τ = ∞ in condition (C.3). By choosing the
optimal σn, we find that the convergence rate of the misclassification rate is a polynomial of order
n, where the order is given by −βq/[β(q + 2) + d(q + 1)] + ρ for any ρ > 0. If furthermore, the
separating boundaries are all completely separable such that β = q =∞, then the convergence rate is
close to n−1, which is the convergence rate of a change point model in parametric models.
2.4 Simulation Studies
We conducted extensive simulation studies to compare FB-SVM with other learning methods.
Specifically, the competing methods included WW in Weston et al. (1999), LLW in Lee et al. (2004),
and one-versus-all (OVA). The RMSVM method in Liu and Yuan (2011) was computationally much
more intensive even with linear kernels so was not included in the comparison. In the simulation
studies, we considered four different scenarios: the first two are taken from Liu and Yuan (2011)
with slight changes, which generates data retrospectively with feature variables X simulated given
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each class of Y . The third and fourth scenario are taken from Lee et al. (2004), which generates data
prospectively with four categories, where feature variables X are simulated first and then the class
label Y is generated based on a multinomial distribution. There were 300 observations (100 for each
category) for the first three scenarios and 400 for the last one. The details of the data generation
are given as follows.
Scenario 1. We considered Y as a 3-class category random variable with equal prevalence, i.e.,
P (Y = 1) = P (Y = 2) = P (Y = 3) = 1/3. Informative feature variable X is 2-dimensional and for
each Y class, the distribution of X is given as:
X|Y = 1 ∼ N((
√
3,−1)T , 1.52I2),X|Y = 2 ∼ N((−
√
3,−1)T , 1.52I2),
and X|Y = 3 ∼ N((0.2, 1)T , 1.52I2),
where I2 is a 2× 2 identity matrix.
Scenario 2. We considered data generation similar to Scenario 1, except that the distribution of
X given Y is from the following:
X|Y = 1 ∼ N((2, 0)T , 1.52I2), X|Y = 2 ∼ N((−2, 0)T , 1.52I2),
and X|Y = 3 ∼ 0.5N((0, 2)T , 1.52I2) + 0.5N((0,−2)T , 1.52I2).
Note that the distribution of X in class 3 is from a mixture normal distribution.
Scenario 3. We considered that X is one-dimensional and from Unif(0, 1). The class label Y is
generated from a multinomial distribution with probabilities
P (Y = 1|X) = 0.95 exp(−6X), P (Y = 2|X) = 0.98 exp{−5(X − 1)2},
and P (Y = 3|X) = 1− P (Y = 1|X)− P (Y = 2|X).
Scenario 4. 4-Category X1 and X2 are both one-dimensional and from Unif(0, 1). The class
label Y is generated from a multinomial distribution with probabilities
P (Y = 1|X) = c(X) exp(−8(X21 + (X2 − 0.5)2)),
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P (Y = 2|X) = c(X) exp(−8((X1 − 0.5)2 + (X2 − 1)2)),
P (Y = 3|X) = c(X) exp(−8((X2 − 0.5)2 + (X1 − 1)2)),
and P (Y = 4|X) = c(X) exp(−8(X22 + (X1 − 0.5)2)),
where c(X) is normalizing function of X so that
∑4
i=1 P (Y = i|X) = 1.
(a) Scenario 1 (b) Scenario 2
(c) Scenario 3 (d) Scenario 4
Figure 2.1: Plots of each simulation setting with Bayes boundaries. Different classes are represented by 3 or
4 symbols and colors
Direct calculation yields that the optimal classification boundary in Scenario 1, 3 and 4 is
linear but is nonlinear in Scenario 2, as shown in Figure 2.1. Additionally, for each setting, we also
considered to include many noise variables unrelated to the class label in order to study the robustness
of each method to noisy data in practice. Specifically, 50 noise variables normally distributed as
N(0, 0.52) and another 50 distributed as N(0, 0.52) + 0.5X1 were added to Scenario 1 and 2; 20 noise
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variables normally distributed as N(0, 0.12) and another 20 with N(0, 0.12) + 0.5X1 were added to
Scenario 3; and 20 noise variables normally distributed as N(0, 0.12) and another 20 distributed as
N(0, 0.12) + 0.5X1 were added to Scenario 4. For each simulated dataset, we applied WW and LLW
using package MSVMpack1.5 in MATLAB (Lauer and Guermeur, 2011). To apply our FB-SVM, we
chose tuning parameter λ among the set {2−5, 2−4, ..., 25}. We considered both linear kernel and
Gaussian kernel in the estimation. The bandwidth of the latter kernel was set to (10d)−1, where d is
the number of features, following the default setting for WW and LLW in MSVMpack1.5. Finally,
to compare the prediction performance of all methods, we generated 5,000 observations independent
for each class as testing data. All software was run on a Linux-based computing system with 2-core,
2.40 GHz Intel processors.
Table 2.1 summarizes the results based on 100 replicates in each simulation setting. Column
“Test Error" is the average of misclassification error rates in the test dataset, and column “Std Dev"
is the corresponding standard deviation from 100 replicates. Column “CPU (sec)" gives the average
CPU running time for each replicate in terms of seconds. The corresponding results with noise
variables are shown in Table 2.2. The corresponding Bayes error (i.e., the optimal misclassification
rate) for these four scenarios is 0.2689, 0.2883, 0.2845 and 0.2798, respectively.
From Table 2.1, it is clear that the proposed method, FB-SVM, outperforms OVA by a large
margin. When there are no noise variables, FB-SVM has similar misclassification rate to WW
and LLW, but much faster to compute (up to more than 100 times improvement in speed). From
Table 2.2 where noise variables are included, FB-SVM with Gaussian kernel continues to achieve
misclassification close to Bayes error. Therefore, FB-SVM is quite robust to the presence of noise
feature variables; however, some competing methods perform worse when noise variables are included.
Although the LLW method has been shown to be Fisher consistent, it does not reveal a better
classification accuracy than FB-SVM. WW has comparable misclassification rate compared to
FB-SVM in this setting, but with a much slower computational speed. The computational time
of our method can be as much as 100-fold faster than LLW and WW. The one-vs-all method has
comparable computational cost as FB-SVM, but it has the lowest classification accuracy among all
the methods.
We also included the results of multinomial regression. For scenarios with no noises, multinomial
regression has comparable test error with FBSVM. However, it yields much higher test errors and
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Table 2.1: Summary of Simulation Results from 100 Replicates (without Noise Variables)
Method Linear kernel Gaussian kernel
Test Err Std Dev CPU (sec) Test Err Std Dev CPU (sec)
Sc 1 FB-SVM 27.3% 0.3% 0.6 28.5% 0.7% 0.9
OVA 31.4% 1.0% 3 34.6% 1.7% 4
WW1 27.2% 0.3% 16 27.5% 0.4% 11
LLW2 30.5% 3.6% 58 27.2% 0.3% 17
MNR3 27.1% 0.2% 0.1
Sc 2 FB-SVM 34.3% 0.4% 0.6 31.1% 0.8% 0.9
OVA 43.6% 0.8% 3 37.8% 1.8% 2
WW 34.3% 0.5% 26 29.8% 0.5% 11
LLW 39.5% 0.1% 72 29.7% 0.4% 18
MNR 40.3% 1.1% 0.1
Sc 3 FB-SVM 29.4% 1.4% 0.2 29.7% 1.6% 0.4
OVA 41.7% 8.7% 0.8 33.9% 6.3% 1
WW 32.0% 1.5% 14 32.6% 0.5% 14
LLW 34.0% 1.1% 26 33.6% 0.9% 26
MNR 28.6% 0.4% 0.1
Sc 4 FB-SVM 29.3% 0.7% 2 29.2% 0.7% 3
OVA 40.5% 1.7% 2 39.6% 4.3% 1
WW 28.3% 0.4% 28 28.5% 0.6% 32
LLW 48.6% 6.9% 37 45.2% 6.7% 47
MNR 28.1% 0.3% 0.1
1 Weston et al., 1999
2 Lee et al., 2004
3 Multinomial regression.
sometimes higher computational cost when the data contain noises. Although multinomial regression
requires the least computational time for most of the time, the results relies heavily on the correctness
of models.
2.5 Applications
2.5.1 Alzheimer’s Disease Data
We applied the proposed method using data collected from the Alzheimer’s Disease Neuroimaging
Initiative (ADNI) (http://adni.loni.usc.edu/; Weiner et al., 2010). The ADNI is a multi-center,
ongoing, prospective study aimed at evaluating clinical, neuroimaging, genetic, and biochemical
biomarkers for Alzheimer’s disease (AD). An important research goal is to use baseline feature
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Table 2.2: Summary of Simulation Results from 100 Replicates (with Noise Variables)
Method Linear kernel Gaussian kernel
Test Err Std Dev CPU (sec) Test Err Std Dev CPU (sec)
Sc 1 FB-SVM 40.3% 1.8% 3 29.6% 0.9% 3
OVA 44.3% 1.7% 1 33.9% 0.8% 2
WW1 40.4% 1.9% 36 28.2% 0.4% 17
LLW2 43.4% 4.4% 127 29.9% 1.2% 33
MNR3 43.8% 1.7% 6
Sc 2 FB-SVM 46.3% 1.3% 3 33.8% 0.4% 3
OVA 48.7% 1.5% 21 40.8% 0.9% 2
WW 46.4% 1.7% 43 34.8% 0.3% 21
LLW 49.6% 4.4% 129 38.0% 1.5% 41
MNR 48.9% 1.3% 7
Sc 3 FB-SVM 32.4% 1.2% 1 32.7% 1.0% 1
OVA 43.4% 1.6% 1 38.1% 1.6% 1
WW 34.3% 1.1% 17 33.1% 0.2% 15
LLW 36.5% 1.5% 32 35.6% 3.1% 29
MNR 36.8% 1.2% 0.3
Sc 4 FB-SVM 34.3% 7.7% 11 36.6% 1.7% 13
OVA 44.0% 9.1% 3 55.4% 3.6% 2
WW 34.6% 7.1% 35 37.2% 2.5% 29
LLW 48.1% 16.4% 60 42.5% 2.2% 43
MNR 39.0% 1.3% 1
1 Weston et al., 1999
2 Lee et al., 2004
3 Multinomial regression.
variables to construct biomarker signatures that can distinguish cognitively normal (CN) healthy
controls, subjects diagnosed as mild cognitive impairment (MCI) at baseline (according to ADNI
protocol) but remained free of AD during the study (non-converters, MCI-nc), subjects diagnosed
as MCI at the baseline but converted to AD during the study (converters, MCI-c), and patients
diagnosed as AD at the baseline. Biomarkers that distinguish MCI-nc and MCI-c are especially useful
for designing clinical trials that target MCI subjects with conversion to AD as the primary endpoint
for the trial. Feature variables included in our analysis were personal health history, cerebrospinal
fluid (CSF) biomarkers, neuropsychological assessments, and magnetic resonance imaging (MRI)
measures. After eliminating missing values, the final analysis dataset contained 98 CN healthy
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controls and 74, 77, and 74 subjects in MCI-nc, MCI-c, and AD category, respectively (a total of 323
subjects). There were 32 feature variables, among which six features were derived from structural
MRI scans (e.g., hippocampal volume). The goal of our analysis is to use all 32 feature variables to
classify subjects into four categories of AD, MCI-nc, MCI-c, and CN. We used linear kernel with
10-fold cross validation to evaluate the performance of FB-SVM and compare it with LLW and
WW. Tuning parameter λ for each binary SVM was selected among the set {2−5, 2−4, ..., 25}. All
continuous variables were standardized before analysis. Classification errors (overall and group-wise),
standard deviation, and the CPU time in minutes are summarized in Table 2.3.
Table 2.3: Averages and standard deviation of the test errors based on 10-fold
cross validation for the ADNI dataset.
Method Test Error Std Dev Misclassification Rate (%) CPU
CN MCI-nc MCI-c AD (min)
FB-SVM 28.8% 6.8% 7.1 20.4 16.8 13.3 0.8
OVA 31.2% 8.6% 5.9 25.7 20.1 10.8 0.3
WW1 29.1% 5.8% 6.5 22.0 20.1 9.6 6
LLW2 35.9% 6.5% 18.6 22.9 18.2 12.1 11
1 Weston et al., 1999
2 Lee et al., 2004
We can see that FB-SVM has the smallest overall test errors. Moreover, the proposed method is
much more efficient and requires the least CPU time. The overall misclassification error for WW is
close to FB-SVM, but for an important category, MCI-c, FB-SVM has a much better performance.
To visualize the classification functions of FB-SVM, we projected the data onto the first two principal
component (PC) directions of the feature variable space in Figure 2.2. In Figure 2.2a, our first step
was to classify group AD from the other groups. In the second step, we kept only those subjects who
had not been classified into AD in the first step and originally from the other 3 groups, and then
classified group CN vs. MCI-nc and MCI-c. In step 3, we kept those subjects who had not been
classified as AD or CN and had observed labels of MCI-nc or MCI-c in order to classify them into
group MCI-nc or MCI-c. It can be seen from Figure 2.2 and Table 2.3 that the most difficult step is
to classify group MCI subjects into converter and non-converter sub-groups. The misclassification
rate for distinguishing MCI-nc and MCI-c is lower for FB-SVM than for WW and LLW. The accuracy
of classifying MCI-nc versus MIC-c using multi-modal ADNI data as reported in the literature, is
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about 67% (Cui et al., 2011), which is lower than that obtained in our analysis. The percentage of
the total variance explained by the first two PCs is 47% and 48% in steps 1 and 2, respectively; and
is 26% explained by the second and third PC in step 3.
(a) Step 1 (b) Step 2
(c) Step 3
Figure 2.2: Principal conponent analysis (PCA) projection plots of FB-SVM classification steps with decision
boundaries in ADNI data. Observed categories are represented by colored dots for correctly classified subjects
and crosses for misclassified subjects from the target group. The background colors red, green, blue, and
yellow mark the areas classified by FB-SVM as CN, MCI-nc, MCI-c, and AD, respectively. Step 1 classifies
AD (black) vs. CN, MCI-nc, or MCI-c. Step 2 classifies CN (blue) vs. MCI-c or MCI-cn. Step 3 classifies
MCI-nc (red) vs MCI-c.
2.5.2 Image Segmentation Data
We considered another application, the Image Segmentation dataset from the UCI Machine
Learning website (https://archive.ics.uci.edu/ml/datasets). The problem to be solved was
classification of image segmentations drawn from 7 outdoor images: 1: brickface, 2: sky, 3: foliage, 4:
cement, 5: window, 6: path, and 7: grass. The images were hand-segmented to create a classification
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for every pixel. Each instance is a 3× 3 region. We removed the third attribute, region-pixel-count,
because the value is 9 for all instances. Thus, the final dataset contained 2310 instances and 18
continuous attributes. Again, 10-fold cross validation and linear rule were used to illustrate the
performance of FB-SVM. Tuning parameter λ for each binary SVM was selected among the set
{2−5, 2−4, ..., 25}. Classification errors (overall and group-wise), standard deviation, and CPU time
in hours are summarized in Table 2.4.
Table 2.4: Averages and standard deviation of the test errors based on 10-fold
cross validation for the Image Segmentation dataset.
Method Test Std Misclassification Rate (%) CPU
Error Dev 1 2 3 4 5 6 7 (hours)
FB-SVM 9.2% 2.0% 0.3 0 4.1 4.5 5.8 3.5 0.3 18
OVA 14.0% 1.8% 10.8 0 2.9 6.3 5.8 7.7 0.2 0.02
WW1 13.7% 2.1% 0.3 5.2 5.4 8.3 6.9 1.0 0.4 110
LLW2 29.1% 2.3% 5.6 3.2 11.9 14.3 13.4 7.7 2.1 10
1 Weston et al., 1999
2 Lee et al., 2004
From Table 2.4, we can see that FB-SVM has the smallest overall test error and competitive
group-wise misclassification rates. OVA has the shortest running time but a worst test error. LLW
requires a shorter computing time than FB-SVM, but has the lowest accuracy; this may be caused
by its limitation on numeric convergence. Steps 1 through 6 in Figure 2.3 illustrate the FB-SVM
classification function projected on the first two PC directions. As described in Section 2, our first
step is to classify group 7 from the other 6 groups. In the second step, we only keep subjects not
classified into group 7 and originally from the other 6 groups, and then classify group 6 versus groups
1 through 5. We complete the classification sequentially for all 7 groups in 6 steps. The classification
functions in each step projected onto the first two PCs and overlaid on the observed class labels are
depicted in Figure 2.3. The percentage of the total variance explained by the first two PCs is 74%,
79%, 83%, 77%, 80%, and 86% from steps 1 through step 6, respectively.
2.6 Conclusions
A number of algorithms are proposed in the literature as extensions of the SVM to solve the
multicategory classification problems. However, most of the existing methods are neither Fisher
consistent nor computationally efficient. In this paper, we propose a novel and computationally
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efficient learning algorithm to perform multicategory classification based on sequential binary SVMs,
which is a convex optimization in each step and converges fast. We also establish the theoretical
properties for the proposed FB-SVM, in terms of being Fisher consistent and the asymptotic
convergence rate. In both simulation and application studies, FB-SVM outperforms alternatives,
with a competitive running time, especially when compared with WW and LLW, where FB-SVM is
seen to be as much as 100-fold faster in some settings.
Although FB-SVM is more computationally efficient when compared with other methods, the
computational cost can be further reduced. One possible approach is to conduct parallel computing
for all permutations in the algorithm in order to achieve a better efficiency, especially for applications
with a large number of categories. Another extension is to explore a more efficient and effective
methodology for a data-driven choice of tuning parameter λ.
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(a) Step 1 (b) Step 2
(c) Step 3 (d) Step 4
(e) Step 5 (f) Step 6
Figure 2.3: PCA projection plots of FB-SVM classification steps with decision boundaries for Image
Segmentation data. Observed categories are represented by colored dots for correctly classified subjects and
crosses for misclassified subjects from the target group. The background colors red, yellow, green, cyan, blue,
purple, and pink mark the areas classified by FB-SVM as groups 1 through 7, respectively.
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CHAPTER 3: SEQUENTIAL OUTCOME-WEIGHTED MULTI
-CATEGORY LEARNING FOR ESTIMATING OPTIMAL ITR
3.1 Introduction
For many chronic diseases such as major depression and type 2 diabetes, treatment heterogeneity
has been well documented where a treatment that is effective in the overall population may be
highly ineffective in a subgroup of patients with specific characteristics (Trivedi Madhukar et al.,
2008), or no longer beneficial after patients develop resistance (Lipska and Krumholz, 2014). On the
other hand, in some cases a newly developed intervention may not be more efficacious compared to
an existing active treatment in the overall population, but may reveal a large benefit in subgroups
of patients (Carini et al., 2014). Henceforth, there has been a growing interest in understanding
treatment heterogeneity and discovering individualized treatment rules tailored to patient-specific
characteristics to maximize efficacy and achieve personalized medicine (Kosorok and Moodie, 2015).
More specifically, tailored treatment strategy aims to recommend optimal treatment decision for an
individual patient using information on a combination of his or her characteristics such as genomic
features, medical treatment history and preference.
Recently, there has been a surge of statistical methods on estimating optimal treatment regimes
involving a single decision point or multiple decision points using data collected from clinical trials
or observational studies (Murphy, 2003; Robins, 2004; Moodie et al., 2007; Qian and Murphy, 2011;
Zhao et al., 2011, 2012; Zhang et al., 2012, 2013). A class of popular methods is regression based
Q-learning (Watkins, 1989; Murphy, 2005; Qian and Murphy, 2011), which relies on some postulated
models to incorporate treatment-by-covariate interactions. Alternatively, Zhao et al. (2012), Zhang
et al. (2012, 2013) proposed machine learning algorithms, for instance, outcome weighted learning
(O-learning), to choose optimal treatment rules by directly optimizing the expected clinical outcome
under the rule, referred as the value function, and draw connection with a classification problem.
Most of these methods are designed to estimate optimal treatment rules for each patient between
two treatment options. However, in many clinical applications it is common that more than two
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treatments are being compared. For example, in our motivating study, Research Evaluating the Value
of Augmenting Medication with Psychotherapy (REVAMP) trial (Kocsis et al., 2009), non-responders
or partial responders to a first-line antidepressant were randomized to three second-line treatment
strategies.
When it comes to multiple-armed trials, the Q-learning approach, which relies heavily on the
correctness of the postulated models, is more prone to model misspecification than for two-armed
trials. For machine learning methods in Zhao et al. (2012), Zhang et al. (2012, 2013), multicategory
treatment decision rules may be obtained via combining one-vs-one or one-vs-all comparisons.
However, it is well documented in multicategory learning literature that the resulting classification
rules from these methods are inconsistent so lead to sub-optimal performance (Dietterich and Bakiri,
1995; Kreßel, 1999; Allwein et al., 2001; Lee et al., 2004; Liu and Shen, 2006), due to possible
conflicted decisions from pair-wise or one-vs-all comparisons. To the best of our knowledge, there
has been no work on using multicategory learning to consistently estimate an optimal individualized
treatment rules (ITRs) for multiple-armed trials.
In this paper, we propose a new approach to estimate optimal ITRs from multiple treatment
options. Specifically, we transform the value maximization problem into a sequence of binary
weighted classifications, which is referred as the sequential outcome-weighed multicategory (SOM)
learning. At each step, we use a weighted binary support vector machine (SVM) to determine the
optimal treatment for patients into one treatment category versus remaining treatment categories,
where the weights are proportional to the outcome values and reflect the fact that a single treatment
category is being compared to one or more treatment categories. We first estimate the optimal rule
for a designated treatment option by excluding the possibility of declaring any other treatment as
optimal via sequential SVMs; next, we exclude the treatments that have been already screened for
optimality and repeat the same learning approach for the remaining treatment options. Theoretically,
we show that the derived treatment rule is Fisher consistent. We demonstrate through extensive
simulations that SOM learning has superior performance in comparison to Q-learning. Finally, an
application of SOM learning to REVAMP shows that an ITR tailored to individual characteristics
such as patients’ expectancy of treatment efficacy and baseline depression severity reduces depressive
symptoms more than a non-personalized treatment strategy.
The rest of the paper is structured as follows. Section 2 introduces the main idea and the
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mathematical framework for multicategory ITRs and formulate the problem for SOM learning. The
detailed algorithm is then provided in the section. In Section 3, we provide theoretical justification
for SOM learning. Sections 4 and 5 present extensive simulations and application to REVAMP to
examine the performance of SOM. Finally, concluding remarks are provided in Section 6. The proof
of theoretical results are presented in the Appendix.
3.2 Methodology
3.2.1 Optimal ITR with multiple treatments
Assume data are collected from a randomized trial with n patients and k different treatment
options. For each patient i, we observe a d-dimensional vector of feature variables, denoted by
Xi ∈ X , a treatment assignment Ai ∈ A = {1, 2, ..., k}, i = 1, ..., n, and the clinical outcome after
treatment denoted by Ri (also referred as the “reward”), with larger values of Ri being more desirable.
A multicategory ITR, denoted by D, is a mapping from the space of feature variables, X , to the
domain of treatments, A. An optimal ITR is a treatment assignment rule that maximizes the
mean reward E[R(D(X))|X], where R(a) is the potential outcome had treatment a been given.
According to Qian and Murphy (2011), for randomized trials and assuming consistency of the








where πa(x) = pr(A = a|X = x) is the randomization probability for treatment a, a = 1, ..., k,,
assumed to be bounded by a positive constant from below, so
∑k
a=1 πa(x) = 1. The goal is to learn
the optimal treatment rule using empirical observations (Ri, Ai, Xi), i = 1, ..., n.
Theoretically, it can be easily shown that the optimal ITR is
D∗(x) = argmaxaE[R|A = a,X = x].
Therefore, one approach to estimate the optimal ITR is using a regression model to estimate the
conditional means on the right-hand side. However, this approach heavily relies on the correctness of
the postulated model, and model misspecification can lead to substantially non-optimal ITR even for
a binary treatment situation (Zhao et al., 2012). Alternatively, Zhao et al. (2012) directly maximized
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the empirical version of the value function but replaced I(A = D(x)) by 1−max(0, 1−Af(x)), where
f(x) is the decision function such that D(x) = sign(f(x)). The latter corresponds to a weighted
support vector machine where the weight for each observation is proportional to Ri. Because of this
connection, the method is referred as outcome-weighted learning (abbreviated as O-learning). They
demonstrated that O-learning outperformed the regression model based method in small sample.
However, the proposed method can only be applied to estimate binary treatment decisions, and
thus not directly applicable when more than two treatment options are of interest. Here, we aim to
develop a robust method based on machine learning, which builds on O-learning for binary decision
rules, to learn optimal multicategory treatment decision rules.
3.2.2 Main idea
The main idea of our method, namely, sequential outcome-weighted multicategory (SOM) learning,
is to perform a sequence of binary treatment decision learning, where each step in the sequence
determines whether the optimal treatment for a patient should be a candidate treatment category or
the other treatments. To illustrate this idea, we order the candidate treatment categories based on
the descending order of their prevalence. Without loss of generality, we assume that the order of the
labels of treatment options are k, k − 1, ..., 1.
We first aim to learn an optimal treatment rule that will determine whether a subject should
be optimally treated with the kth option. Equivalently, we partition the domain of X into Xk and
X ck such that for subject with feature values X ∈ Xk, the optimal treatment is the kth option; and
for subject with X ∈ X ck , the optimal treatment is not the kth option. To this end, we consider
any ordered sequence of {1, ..., k − 1}, denoted by {j1, ..., jk−1}, and let jk = k. A sequential ITR
learning is then conducted as follows.
In the first step, starting with j1 versus {j2, ..., jk}, we determine whether a subject should be
treated optimally with the j1th option or some other choice. Since this is a binary decision problem,
we can use existing methods for learning a binary treatment decision rule, for example, O-learning,
with additional modifications as explained in later section. With this binary rule, for a future
patient with feature variables X, if he or she is assigned to treatment j1 6= k, then clearly, X ∈ X ck .
Otherwise, we cannot determine whether X should be in Xk or X ck , since his/her optimal treatment
can be one of j2, ..., jk.
In the second step of this sequential learning, we only consider patients whose optimal treatments
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are not determined as j1 in the previous step. We then aim to learn a binary treatment rule to
decide whether this subject should be optimally treated with j2 or the remaining treatment choices,
{j3, ..., jk}. Again, this is a binary treatment decision problem so we can perform estimation similar
to the first step. With the second decision rule, we can check whether the patient should be treated
with j2 or some treatment among the remaining options. If j2 6= k is selected, we conclude X ∈ X ck ;
otherwise, we are still uncertain whether X ∈ Xk.
Continue this process sequentially in the third step till the kth step when there is only treatment
category k in consideration. Consequently, for this given sequence, {j1, ..., jk−1}, the optimal
treatment for this patient is k, i.e., X ∈ Xk, if and only if at each step, the binary decision learning
concludes that the patient should not be treated by j1, j2, ..., jk−1 in turn. The choice of the ordered
sequence {j1, ..., jk−1} is arbitrary, so we propose to consider all possible permutations of {1, ..., k−1}.
Then a patient with X should be treated with treatment k once he/she is determined to have the
kth option as the optimal treatment in at least one permuted sequence.
The above procedure only provides a treatment rule that decides whether a subject has the
optimal treatment as k (X ∈ Xk) or some other option (X ∈ X ck ). Thus, for a subject with features
X ∈ X ck , we need to determine which of the remaining {1, ..., k − 1} options is optimal. This can
be carried out using the following procedure. We only consider patients whose optimal treatment
is not k based the previous procedure and whose actual treatments received are not k. For these
patients, the optimal treatment options can only be one of {1, ..., k − 1}, so the goal reduces to
finding the optimal treatment decision within (k − 1) categories. Therefore, we can repeat the
previous procedure but consider treatment (k − 1) as the target in treatment optimization. At the
end, we obtain a treatment rule that determines whether a subject should be optimally treated with
(k − 1). Finally, the same procedure can be carried out sequentially to decide which patients have
the optimal treatment as (k − 2), . . . , 1, in turn.
Clearly, an advantage of SOM learning is that at every step of the sequential learning, one only
needs to learn a binary decision rule, and thus many learning algorithms for binary decision are
applicable. In particular, in our subsequent algorithm and implementation, we adopt the method
from O-learning (Zhao et al., 2012) to use a weighted support vector machine (SVM) for this purpose.
However, one significant difference is that due to the multicategory nature, weights in SOM learning
should not only be proportional to the outcome R as in O-learning, but should also reflect the
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imbalanced comparison between one treatment category and the combination of multiple treatment
categories. The latter ensures that the derived optimal treatment rule is Fisher consistent, as will be
shown in Section 3.
3.2.3 Method and algorithm
Mathematically, we can express SOM learning algorithm as follows. Start from the target decision
for treatment k. Consider the jth permutation {j1, ..., jk−1}, and let jk = k. The main algorithm is
as follows:
1. At step 1, recall from the previous section that our goal is to learn a binary rule to decide whether
a future patient should be treated by option j1. Intuitively, we shall estimate the optimal decision
function f∗j1(X) such that the corresponding value for this decision, i.e.,
E [RI{Zj1fj1(X) > 0}/πA(X)] ,
is maximized with Zj1 = 2I(A = j1)− 1. According to Liu et al. (2014), even if R may be negative,
this maximization is equivalent to minimize











I{Zj1sign(R) = −1}{1 + fj1(X)}
]
.
Thus, using the empirical data, we may consider minimizing the empirical version the above
expectation. However, there are two important issues to be considered. First, since solving the
above problem is NP-hard, we can use a weighted SVM which essentially replaces the above 0-1
loss with a continuous and convex hinge-loss function. Second, since this learning is comparing one
treatment category versus (k− 1) categories, it is necessary to weight observations with treatment j1
by (k − 1)/k and the others by 1/k in order to balance the comparison.
Therefore, our algorithm is as follows following the above rationale. We define πjl(x) = pr(A =
jl|X = x), where l = 1, ..., k, and let Zijl = 2I(Ai = jl)− 1. We then estimate the optimal decision

































l=2 I{Ai = jl}πjl(Xi), x+ = max(x, 0) is the hinge loss, ‖ · ‖ denotes a semi-norm
for f and λnj1 is a tuning parameter. Particularly, consider a linear decision rule, i.e., f(x) = βTx+β0,
‖f‖ is chosen as the Euclidean norm of β; if a nonlinear decision rule is desired, f will be chosen
from a reproducing kernel Hilbert space and ‖f‖ is the corresponding norm in that space.
2. At step 2, recall from the previous section that this step aims to find the optimal decision to be
either treatment j2 or one of {j3, ..., jk} among those patients whose optimal treatments are not
determined as j1 from step 1. Thus, restrict the data to those subjects who do not receive the j1th
treatment and whose optimal treatments are not j1 as from the previous step. We then estimate a





































l=3 I{Ai = jl}πjl(Xi), Zijl , πjl(Xi) are defined as same as in step 1, and λnj2 is a
tuning parameter. Note that in addition to weights based on the outcome values, we also weigh the
observations from treatment j2 by (k − 2)/(k − 1) and the others by 1/(k − 1) in order to account
for the fact that the decision rule is based on comparing one category versus (k − 2) categories.
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l=h+1 I{Ai = jl}πjl(Xi), Zijl , πjl(Xi) are defined as same as above steps. Again,
we use weight (k − h)/(k − h+ 1) for treatment jh versus 1/(k − h+ 1) for the others to balance
comparison. At the end of this sequence, we conclude that if
f̂j1(x) < 0, f̂j2(x) < 0, ... f̂jk−1(x) < 0,
the optimal treatment for a patient with features x will be the kth option, the pre-determined
target treatment category. For notational simplification, we denote D̂k(j1,...,jk−1)(x) = 1 if the above
conditions hold and let D̂k(j1,...,jk−1)(x) = −1 otherwise.
The choice of this sequential decision rule is based on the permutation (j1, ..., jk−1), and thus
may not exhaust the correct optimal treatment assignment for the kth option due to a specific
choice. We thus repeat the above sequential learning for any possible (k− 1)! permutations to obtain
D̂k(j1,...,jk−1)(x). Consequently, our final decision rule to assign a patient with treatment k if and only
if D̂k(j1,...,jk−1)(x) = 1 for at least one permutation (j1, ..., jk−1). That is, if we define
D̂k(x) = max
(j1,...,jk−1) is permutation of{1,..,k−1}
D̂k(j1,...,jk−1)(x),
then the optimal treatment for patient with x is treatment k if and only if D̂k(x) = 1.
4. To determine whether a patient should be optimally treated with the (k− 1)th option, we adopt a
backward elimination procedure. We exclude the patients who receive treatment option k or whose
optimal treatments are determined as k in the previous step. In other words, we restrict the data
to subjects with Ai 6= k and D̂k(xi) = −1. Because the data consist of only (k − 1) treatment
options, we use the same SOM learning procedure as before but now set option (k − 1) as the target
treatment, i.e., the last category in consideration in the above sequential learning algorithm. By this
procedure, we obtain a decision rule at each step for each permutation of {1, .., k − 2}, denoted by




Consequently, the optimal treatment for a patient with x is (k − 1) if and only if D̂(k−1)(x) = 1 and
D̂(k)(x) = −1.
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5. Continue this backward elimination and sequential learning in turn for treatment (k − 2), ..., 1 so
as to obtain D̂(k−2)(x), ..., D̂1(x). Our final estimated optimal ITR is
D̂(x) =

k D̂(k)(x) = 1
k − 1 D̂(k)(x) = −1, D̂(k−1)(x) = 1
...
...
2 D̂(k)(x) = −1, . . . , D̂(3)(x) = −1, D̂(2)(x) = 1
1 D̂(k)(x) = −1, . . . , D̂(3)(x) = −1, D̂(2)(x) = −1.
Our algorithm for k-category SOM learning can be summarized as follows:
Backward loop with target class s ∈ {k, ..., 1}:
Inner loop: for each permutation of the remaining treatment assignments except the
previously classified ones and target treatment label s , perform a sequence of weighted
O-learning to learn D̂(j1,...,js−1)(x) for each permutation (j1, ..., js) of {1, .., s}.
Collect all rules to obtain D̂s(x) = max(j1,...,js−1)∈Πs−1 D̂s(j1,...,js−1)(x).
After eliminating all samples with actual treatment labels are previously considered treatment
or whose optimal treatments are within any of the previous labels, go to the backward loop
step.
We note that SOM learning requires a total of
k∑
l=1
(l − 1)× (l − 1)! = k!− 1
weighted binary SVM classifications. However, because of the sequential exclusion of subjects,
the size of the input data decreases in a proportional fashion. Therefore, SOM learning can be
computationally efficient due to the fast implementation of SVM and reduced data sizes in each




In this section, we first establish the Fisher consistency of the optimal ITR estimated using SOM
learning. Next, we obtain a risk bound for the estimated ITR and show how the bound can be
improved for certain situations.
3.3.1 Fisher consistency
We provide the theoretical property of Fisher consistency for the proposed SOM learning.
Specifically, when the sample size is infinity, we show that the derived ITR is the same as the true
optimal ITR
argmaxkl=1E(R|X = x,A = l).
Let f∗jl(x) be the counterpart of f̂jl(x) in the SOM learning procedure when n =∞ and the tuning
parameters vanishes. Let D∗l(j1,...,js)(x) and D
∗l(x) be the corresponding limits of D̂l(j1,...,js)(x) and
D̂l(x), respectively, when n =∞. Then the limit of the ITR from SOM learning is
D∗(x) =

k D∗(k)(x) = 1
k − 1 D∗(k)(x) = −1,D∗(k−1)(x) = 1
...
...
2 D∗(k)(x) = −1, . . . ,D∗(3)(x) = −1,D∗(2)(x) = 1
1 D∗(k)(x) = −1, . . . ,D∗(3)(x) = −1,D∗(2)(x) = −1.
The following result holds.
Theorem 3.1. SOM learning rule D∗(X) is Fisher consistent. That is, D∗(x) = l if and only if
E(R|X = x,A = l) = maxkh=1E(R|X = x,A = h) for l = 1, ..., k.
Theorem 1 provides a theoretical justification that the proposed SOM learning yields the true
optimal ITR asymptotically. The proof of Theorem 1 is given in the appendix. The key result is to
show that at each step of SOM learning, we compare the conditional mean E[R|X,A = j1] with the
average value of E[R|X,A = j2], where j1 is the treatment category in consideration at this step
while j2 is any treatment category among the remaining options.
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3.3.2 Risk bounds





I {A 6= D(X)}
]
where j = 1, ..., k, πA(x) =
∑k
j=1 I(A = j)pr(A = j|x); and let R∗ = R(D∗). Clearly, R(D) and R∗
correspond to E[R] subtracting the value for D and D∗, respectively. In the section, we will derive
the convergence rate of the estimated value function from the optimal value, which is equivalent
to R(D̂)−R∗, under some regularity conditions and assuming that the functional spaces for fjl in
our SOM learning are from a reproducing kernel Hilbert space (RKHS) with Gaussian kernel and
bandwidth 1/σn.
For any l and subset, S, in {1, ..., k} where l /∈ S, we define
ηl,S(x) =
E(R|X = x,A = l)
|S|−1
∑
h∈S E(R|X = x,A = h)
,
where |S| denotes the cardinality of S. That is, ηl,S(x) is the ratio between the mean outcome in
treatment arm l and the average mean outcome in treatment options from S. We assume that the
following conditions hold:
Condition 3.1. (Geometric noise conditions) There exist q, β > 0, and a constant c such that for
any l and set S with l /∈ S, it holds that
r









) ∣∣∣ηl,S(X)− 1∣∣∣} ≤ ctβ,
where ∆(X) denotes the distance from X to the boundary defined as {x : ηl,S(x) = 1} .
Condition 3.2. The distribution of X satisfies tail component condition pr(|X| ≥ r) ≤ cr−τ for
some τ ∈ (0,∞] and E(|R||A = a,X = x) is uniformly bounded away from zero and infinity.
Condition 3.3. There exists λn such that λn → 0 and nλn →∞. Moreover, all tuning parameters
λnj’s in SOM satisfy M−1λn ≤ λnj ≤Mλn for a positive constant M . We further assume σn →∞.
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Remark 3.1. In condition (3.1), the constants q and β are called noise exponent and marginal noise
exponent, respectively. They are used to characterize the data distribution near the decision boundary
at each step of SOM where we compare treatment jl versus any subset of {jl+1, ..., jk}. In particular,
when the boundary is fully separable, that is, |ηl,S − 1| > δ0 for a constant δ0, these conditions hold
for q = β =∞. In condition (3.2), τ describes the decay of the distribution of X. Obviously, when
X is bounded, τ =∞. Condition (3.3) assumes the choice of tuning parameter and bandwidth in
RKHS. We choose this simplification for convenience, although we can allow the tuning parameter
and bandwidth to be different for each treatment decision in the proposed method. Under conditions
(3.1)-(3.3), the following theorem holds.
Theorem 3.2. Under conditions (3.1)-(3.3), for any ε0 > 0, d/(d + τ) < p ≤ 2, there exists a
constant C such that for any ε > 1 and σn = λ
−q/(2β(1+q))
n , with probability at least 1− e−ε,

















Remark 3.2. Suppose that X is bounded such that τ = ∞ in condition (3.2). By choosing the
optimal λn for the last two term in the right-hand side, i.e., λn = n−(1+q)/(1+2q), we find that the
convergence rate is a polynomial order of n, where the order is q/(1 + 2q). If furthermore, the
separating boundaries are all completely separable such that q =∞, then the convergence rate is close
to the square-root rate.
3.4 Simulation Studies
We conduct extensive simulation studies from four different settings to examine the small-sample
performance of SOM learning. In the first three settings, 20 feature variables are simulated from
a multivariate normal distribution, where the first 10 variables X1, X2, ..., X10 have a pairwise
correlation of 0.8, the remaining 10 variables are uncorrelated, and the marginal distribution for each
variable is N(0, 1). We generate 3-category random treatment assignments with equal probability,
i.e. pr(A = 1|X) = pr(A = 2|X) = pr(A = 3|X) = 1/3. The reward functions for the first three
settings are generated as follows:
Setting 1. R = X4 + (X1 +X2)I(A = 2) + (−X1 +X3)I(A = 3) + 0.5×N(0, 1)
Setting 2. R = X4 + (X22 −X21 )I(A = 2) +X33I(A = 3) + 0.5×N(0, 1)
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Setting 3. R = (X1 − 0.2)× {I(A = 1)− I(X1 > 0.3)}2 + (X2 + 0.3)× {I(A = 2)− I(X2 >
−0.5)}2 + (X3 + 0.5)× {I(A = 3)− I(X3 > 0)}2 + 0.5×N(0, 1).
In the last setting (Setting 4 ), we imitate a situation where the entire population consists of
a finite number of latent subgroups for which the optimal treatment rule is the same within each
subgroup. Specifically, we consider 10 latent groups and the true optimal treatment category of each
group is, in turn, A∗ = 3, 3, 1, 2, 2, 1, 2, 3, 3, 1. To generate data mimicking a three-arm randomized
trial, for each subject, a 3-category treatment A, is randomly assigned with equal probability. The
reward outcome is generated as R = 4× I(A = A∗)− 1 + 0.5×N(0, 1). Furthermore, we imitate
a common real world scenario where the treatment mechanism may not be known and thus the
latent subgroup labels are not observed: instead of directly using group labels as observed data, we
generate feature variables that are informative of the latent group membership as observed data. We
simulate 30 feature variables from a multivariate normal distribution, where the first 10 variables
X1, X2, ..., X10 have a pairwise correlation of 0.8, the remaining 20 variables are uncorrelated, and
the variance for each variable is 1. Moreover, X1, X2, ..., X10 have mean values of µl for the latent
group l, which are generated from N(0, 5), while the means of X11, ..., X30 are all 0s. Therefore,
only X1, X2, ..., X10 are informative of the group labels due to different µl. The observed data for
each subject consist of the treatment assignment A, the feature variables X1, ..., X30, and the reward
outcome R.
For each simulated data, we apply SOM learning to estimate the optimal ITR. At each step, we
fit a weighted SVM with a linear kernel by solving the corresponding dual problem via quadratic
programming. The tuning parameter is chosen using cross-validation. Furthermore, we compare
SOM learning with regression-based Q-learning, one-vs-all (OVA) and one-vs-one (OVO) based
on the value function (reward) of the estimated optimal treatment rules. Q-learning is obtained
by fitting a linear model, regressing R on X, A and their interactions, in which A is replaced by
dummy variables created for each category of A. For OVA and OVO, to make sure the rewards are
positive, we use the absolute value of rewards as weights, and for each binary step, new labels are
calculated by multiplying the original labels with signs of reward. This approach is extracted from
our SOM learning. Then the estimated value functions are obtained from weighted binary SVM
models. Because both OVO and OVA algorithms break multi-treatment problems down to binary
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ones, the main drawback is that if a subject is assigned with more than one treatment through
different binary comparisons, the final assignment will be the one with the smallest label value. For
each setting, we compare the four methods with different sample sizes: n =300, 600, and 900.
Figure 3.1 to 3.4 present the results of the optimal treatment mis-allocation rates and the
estimated value functions from 100 replicates and difference sample sizes, which are computed in an
independently generated test data of size 3 million. Furthermore, Table 3.1 to 3.4 summarize the
average of the marginal mis-allocation rates of each category.
In the first setting, we observe that Q-learning gains higher values and lower mis-allocation rates
of the optimal ITR compared to SOM under all sample sizes because the regression model used in
Q-learning is correctly specified. The estimated values of SOM learning become closer to those of
Q-learning as the sample size increases. In the latter three non-linear settings, the regression model
in Q-learning is misspecified, so it performs worse under all sample sizes. Instead, SOM learning
outperforms all comparators including OVA and OVO in all the simulation settings. For SOM
learning, we also used Gaussian kernel in our method and found negligible difference from using
linear kernel. However, since computation using the former is much more intensive, we recommend
to use linear kernel in practice.
Table 3.1: Category Mis-allocation Rates (%) of Setting 1
Cat n=300 n=600 n=900SOM Qlearn OVA OVO SOM Qlearn OVA OVO SOM Qlearn OVA OVO
1 19.6 10.9 41.3 23.3 14.6 7.4 40.1 17.8 12.7 6.0 39.6 15.3
2 12.6 5.4 19.3 14.5 10.5 3.6 16.8 11.6 9.8 2.9 16.0 10.5
3 23.2 10.7 31.7 25.3 16.5 7.2 30.6 18.9 14.4 5.9 29.4 16.0
Table 3.2: Category Mis-allocation Rates (%) of Setting 2
Cat n=300 n=600 n=900SOM Qlearn OVA OVO SOM Qlearn OVA OVO SOM Qlearn OVA OVO
1 23.8 27.7 41.4 31.2 20.9 27.1 42.1 31.0 19.0 26.7 40.4 30.3
2 34.4 38.8 39.3 39.8 30.7 38.8 38.9 39.4 29.0 38.5 38.9 39.0
3 23.1 19.0 22.4 21.1 21.3 17.0 20.7 19.5 20.3 16.3 18.7 18.3
3.5 Application to REVAMP Study
We evaluate the performance of various methods when applied to the motivating REVAMP trial
(Kocsis et al., 2009). The study aimed to evaluate the efficacy of adjunctive psychotherapy in the
36
Figure 3.1: Box plots of the optimal treatment mis-allocation rates and estimated value functions of
SOM, Q-learning, OVA and OVO for setting 1 with sample size of 300, 600 and 900. The optimal
value is 0.9245.
treatment of patients with chronic depression who have failed to fully respond to initial treatment
with an antidepressant medication. Among 808 participants in phase I, 491 were nonresponders or
partial responders and entered phase II. At phase II, these 491 participants were then randomized
to receive (1) continued pharmacotherapy and augmentation with brief supportive psychotherapy
(MEDS+BSP), (2) continued pharmacotherapy and augmentation with cognitive behavioral analysis
system of psychotherapy (MEDS+CBASP), or (3) continued pharmacotherapy (MEDS) alone, and
were followed for 12 weeks. The primary outcome was the Hamilton Scale for Depression (HAM-D)
scores at the end of 12-week follow-up. There were 17 baseline feature variables including participants’
demographics, patient’s expectation of treatment efficacy, social adjustment scale, mood and anxiety
symptoms, and depression experience, as well as phase I depressive symptom measures such as rate
of change in HAM-D score over phase I, HAM-D score at the end of phase I, rate of change of Quick
Inventory of Depression Symptoms (QIDS) scores during phase I, and QIDS at the end of phase I.
After excluding participants with missing data, the final analysis consists of 318 participants,
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Table 3.3: Category Mis-allocation Rates (%) of Setting 3
Cat n=300 n=600 n=900SOM Qlearn OVA OVO SOM Qlearn OVA OVO SOM Qlearn OVA OVO
1 28.1 31.0 35.1 35.8 25.4 27.7 34.6 31.7 23.7 25.7 36.6 29.9
2 33.0 39.1 36.7 40.0 31.5 38.2 36.9 38.6 30.3 37.5 36.2 37.6
3 38.5 38.8 37.2 40.7 36.6 36.6 37.0 38.7 36.0 36.1 36.9 39.5
Table 3.4: Category Mis-allocation Rates (%) of Setting 4
Cat n=300 n=600 n=900SOM Qlearn OVA OVO SOM Qlearn OVA OVO SOM Qlearn OVA OVO
1 14.7 35.7 43.3 30.6 13.1 33.0 43.6 30.2 13.2 31.2 44.3 28.6
2 27.5 37.5 30.9 32.0 25.7 34.8 29.4 31.2 25.1 33.4 29.0 30.8
3 33.9 37.1 33.4 32.0 32.6 34.8 32.8 31.8 31.9 34.0 32.3 31.4
among whom 134, 123, and 61 were assigned in MEDS+BSP, MEDS+CBASP, and MEDS, respec-
tively. The mean HAM-D at the end of phase II study in each treatment arm under the designed
non-personalized, random treatment assignment is summarized in Table 3.5. MEDS+CBASP group
has the lowest post-treatment HAM-D score, but there is no statistically significant differences in
the changes of HAM-D scores during phase II detected among the 3 treatment groups (Kocsis et al.,
2009).
Table 3.5: Mean (standard error) of the HAM-D under randomized treatment assignment and value
function of ITR from 2-fold cross-validation procedure with 500 repetitions
Treatment arm† MEDS+BSP MEDS+CBASP MEDS
Value in test sample∗ 13.51 (0.05) 10.75 (0.05) 12.66 (0.13)
Method for ITR SOM learning Q-learning OVA OVO
Value in test sample∗ 8.91 (2.91) 16.16 (2.64) 12.18 (1.67) 10.85 (2.24)
†: Treatment arm under the designed non-personalized, random assignment rule. ∗: Value function is the average
HAM-D score at end of phase II for patients following an estimated optimal treatment (a smaller HAM-D score
indicates a better outcome).
Our analysis goal is to use 17 feature variables to estimate the optimal ITR among three different
options so that the value function (average HAM-D scores) under the ITR can be as low as possible.
All feature variables are standardized before the analyses. We apply SOM learning and compare with
Q-learning that uses (1, X,A,XA) in the regression model, where X represents feature variables and
A is the randomized treatment assignments, as well as OVA and OVO. The expected HAM-D for an
ITR is calculated from 2-fold cross-validation of the data with 500 replicates: at each replicate, we
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Figure 3.2: Box plots of the optimal treatment mis-allocation rates and estimated value functions of
SOM, Q-learning, OVA and OVO for setting 1 with sample size of 300, 600 and 900. The optimal
value of setting 2 is 1.0585.
randomly split the data into a training sample and a testing sample; we then apply SOM learning to
learn the optimal ITR using the training data and compute the expected value in the testing sample
under this estimated rule. The averages of the cross-validated value functions from the four methods
are presented in Table 3.5 and their distributions over cross-validations are plotted in Figure 3.5.
With a value function of 8.91, the SOM learning achieves a lower HAM-D compared to Q-learning,
OVA, OVO, and any of the non-personalized, random assignment rules.
There are 99, 103, and 116 patients predicted to have MEDS+BSP, MEDS+CBASP, and MEDS
alone as the optimal treatment, respectively. Table 3.6 presents the coefficients of the 3!− 1 = 5
models derived from SOM learning rule in REVAMP study. Model 1 and model 2 corresponds to the
2 permutations of inner loop, determining whether a subject should be optimally assigned to MEDS
only group or not. After eliminating the possibility of being assigned to MEDS only group, model 3
assigns a subject into MEDS+BSP or MEDS+CBASP treatment group. Let β̂11, β̂12, β̂21, β̂22, β̂3 be
the estimated coefficients of model 1(1), 1(2), 2(1), 2(2) and 3, respectively. A patient will be assigned
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Figure 3.3: Box plots of the optimal treatment mis-allocation rates and estimated value functions of
SOM, Q-learning, OVA and OVO for setting 1 with sample size of 300, 600 and 900. The optimal
value of setting 3 is 1.1438.
with: MEDS if he has {XT β̂11 < 0, XT β̂12 < 0}, or {XT β̂21 < 0, XT β̂22 < 0}; MEDS+CBASP if he
has not been assigned to MEDS and XT β̂3 < 0; MEDS+BSP if he has not been assigned to MEDS
and XT β̂3 > 0. The column “Norm" reports the overall effect of feature variables on the optimal
treatment decision rule as the L2-norm of all coefficients for predicting each model.
The overall most predictive variable as determined by the norm of the coefficients in estimating
the optimal ITR is phase I QISD rate of change, followed by phase I HAM-D rate of change. Both
variables are most predictive of patients with MEDS alone as the optimal choice compared to
two other combined pharmacotherapy and psychotherapy. Gender, response at phase I, patients
expectancy of treatment efficacy, and CBASP expectation are also informative with an overall
effect size greater than 0.7. Gender is also most predictive of MEDS alone versus two combined
therapies alternatives with females favoring the latter. Other predictive variables include history of
drug abuse and current alcohol use. No feature variable has a substantially large effect in model 3,
implies that potentially many variables are in play to distinguish MEDS only versus the other two
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Figure 3.4: Box plots of the optimal treatment mis-allocation rates and estimated value functions of
SOM, Q-learning, OVA and OVO for setting 1 with sample size of 300, 600 and 900. The optimal
value of setting 4 is 2.9999.
combined therapies. In a recent analysis ofanother randomized trial on major depressive disorder
comparing Nefazodone, CBASP or the combination of the two treatments, obsessive compulsive and
past history of alcohol dependence (Gunter et al., 2011), race, and education level (Klein et al., 2011)
are identified as predictive by Q-learning, which partially corroborates our findings. Our analyses
identify several additional feature variables as informative.
To further visualize the relationship between feature variables and the optimal treatment for each
individual, in Figure 3.6, we present the heatmap of 17 standardized feature variables by predicted
optimal treatment on all subjects. We can see that history of drug abuse has a different pattern
between patients with MEDS+BSP as optimal choice and the other two groups (more prevalent in
the former versus the latter two groups), and thus may be informative of distinguishing MEDS+BSP
versus others; dysfunctional attitudes, and patient’s treatment efficacy expectation, frequency of
sides effects, HAM-D rate of change during phase I, QIDS and HAM-D end of phase I score are
informative for distinguishing all three treatments. It is clear that no single variable has a dominating
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Figure 3.5: Box plot of the value function for the optimal ITR estimated by various methods from
2-fold cross-validation with 500 repetitions using REVAMP data: HAM-D score after phase II
treatment (a smaller score indicates a better outcome).
effect on estimating the optimal ITR, and all feature variables in combination may be more effective.
3.6 Conclusions
We have proposed a sequential outcome weighted learning, SOM learning, to estimate the
optimal ITRs with multicategory treatment studies, where each step solves a weighted binary
classification problem via SVMs. By carefully choosing weights in each SVM step and combining
the treatment decision functions from all steps, we showed that the derived rule from the proposed
learning algorithm is Fisher consistent. In contrast to other Fisher consistent mutli-category learning
algorithms (e.g., Liu and Shen, 2006), our method does not require non-convex optimization. In
both numeric simulations and data application, SOM learning yields a more desirable value function
as compared to the method based on a standard regression model or other straightforward methods
such as one-vs-one and one-vs-all.
SOM learning can be extended in several directions. First, for some chronic diseases with
multi-stage therapy, dynamic treatment regimes (DTRs) can be more powerful in obtaining favorable
outcomes than a simple combination of single-stage treatment rules. Various approaches have been
developed to estimate optimal DTR, such as Murphy (2003); Robins (2004); Moodie et al. (2007);
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Table 3.6: Coefficients estimated from SOM learning in REVAMP study (ranked by the overall effect
of a feature variable).
Feature Variable Model 1(1) Model 1(2) Model 2(1) Model 2(2) Model 3 Norm∗
QISD phase I change -0.1281 0.0765 0.1200 2.2308 -0.1338 2.2430
HAM-D phase I change -0.0063 0.0050 0.0285 1.7769 -0.0252 1.7773
Gender (Male) -0.2726 -0.0565 -0.0880 -1.0370 0.0753 1.0800
Phase I response -0.2269 -0.0147 0.0166 -0.7567 -0.0382 0.7913
Tx efficacy expectation 0.4010 0.1026 0.1232 0.5791 0.0268 0.7229
CBASP expectation -0.2767 -0.0153 0.0093 -0.6371 -0.1444 0.7097
History of drug abuse 0.3187 0.0199 0.0017 0.5644 0.0648 0.6517
Current alcohol use 0.3159 0.0100 -0.0801 0.0877 0.2214 0.4038
Social adjustment 0.0813 0.0481 0.1075 -0.3202 -0.0207 0.3513
BSP expectation 0.1498 -0.0349 -0.0542 0.2703 0.1087 0.3338
Freq of side effects -0.0189 0.1816 0.1394 0.0909 -0.1199 0.2746
QISD end of phase I 0.1999 -0.0216 -0.0796 0.1259 0.1005 0.2697
Anxious Arousal 0.0957 0.1316 0.1227 0.0850 -0.0069 0.2209
General Distress Anxious -0.0975 -0.0900 -0.0954 -0.0844 -0.0085 0.1842
HAMD end of phase I -0.0449 -0.0101 0.0108 -0.0798 -0.0520 0.1063
Dysfunctional Attitudes -0.0099 0.0041 0.0058 -0.0108 -0.0049 0.0170
Age 0.0017 -0.0001 -0.0009 0.0011 0.0018 0.0029
∗: “Norm" measures the overall effect of a variable on the optimal treatment assignment rule as the L2 norm of all
coefficients for predicting each model.
Zhao et al. (2011); Zhang et al. (2012, 2013); Liu et al. (2014). While our method has focused on
single-stage studies only, the proposed procedure can be easily generalized to handle multicategory
DTR for multiple stage trials. Second, although the proposed method was only applied to a finite
number of categories, it can be naturally extended to find optimal personalized dose, where treatment
is in a continuous scale, after discretizing the dosage into categories. However, one challenge is
to determine the number of the categories and the threshold of discretization. A possibility is to
include these uncertainties as parameters to by estimated in SOM learning. Further research is
worth pursuing.
A major computational cost for SOM learning is to screen all possible permutations of the
treatment categories. Since the sequential learning for each permutation can be carried out indepen-
dently of one another, an improvement in implementation is to incorporate distributed computing to
leverage this natural parallel computing structure.
Finally, although we suggested to treat the most prevalent treatment as the first target optimal
treatment in SOM learning procedure, this may result in few cases for later treatments in consideration
and cause a large mis-allocation rate for patients whose optimal treatments are less prevalent. In
practice, when different treatments have different importance, for instance, due to the need to
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Figure 3.6: Heatmap of 17 standardized feature variables on all patients grouped by predicted optimal
treatment. Row corresponds to feature variable and column corresponds to patients stratified by
predicted optimal treatment.
balance efficacy and risk, the order of the targeted treatments should take into account the practical
importance.
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CHAPTER 4: MULTICATEGORY LEARNING FOR ESTIMATING
OPTIMAL ITR FROM ELECTRONIC HEALTH RECORD DATA
4.1 Introduction
4.1.1 Adverse drug reaction and EHR data
Adverse drug reactions (ADR) due to drug side effects and drug-drug interactions has become
an increasing burden and threat to global public health. A recent study showed that in the United
Kingdom, ADRs account for 1 in 16 of all hospital admissions (Pirmohamed et al., 2004). Moreover,
drug-drug interactions particularly elevate the risk of ADRs. Although many of the implicated
drugs have proved benefit, measures need to be put into place to reduce the burden of ADRs and
thereby further improve the benefit:harm ratio of the drugs. It has been well documented that,
in some cases, a treatment that is effective in the overall population may be highly ineffective in
a subgroup of patients with specific characteristics, or no longer beneficial after patients develop
resistance (Trivedi Madhukar et al., 2008; Lipska and Krumholz, 2014). In recent years, there is a
growing interest in understanding treatment heterogeneity and discovering individualized treatment
rules (ITRs) to maximize efficacy and achieve personalized medicine (Kosorok and Moodie, 2015).
Particularly, individualized treatment strategy aims to recommend optimal treatment decision for an
individual patient using information on a combination of his or her characteristics such as genomic
features, medical history etc. Given patients’ characteristics, searching for their optimal treatments
could be one of the solutions to reduce the risk of having ADRs during or after drug use.
To estimate the optimal ITRs and handle high-dimensional patient-level feature variables,
numerous machine learning methods are proposed. One popular method is Q-learning (Watkins,
1989; Murphy, 2005; Qian and Murphy, 2011), which relies on regression models to incorporate the
interactions between treatment and covariates. However, because Q-learning relies heavily on the
correctness of models, it may perform poorly when the model is misspecified. Another frequently
used approach is outcome weighted learning (O-learning) proposed by Zhao et al. (2012). O-learning
is an algorithm based on weighted support vector machines, to choose optimal ITRs by drawing a
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connection to a classification problem and directly optimizing the expected clinical outcome under
the rule. We propose sequential outcome-weighted multicategory learning (SOM-learning) in Chapter
3, which generalizes O-learning to settings with more than two treatment options, and also allows
negative outcome values. We also provide the convergence rate of SOM-learning and prove the
Fisher consistency of the estimated ITR.
Electronic health records (EHR) provide rich resources to enable understanding of various clinical
problems in real world setting including adverse drug reactions. Because of a greater availability at
lower costs and technological advances that made computational processing on large-scale data more
feasible, EHR databases have been actively used in pharmacoepidemiology especially for the past
decade (Madigan et al., 2014). Relative to individual case safety reports, EHR data cover extended
parts of the underlying medical histories, include more complete information on potential risk factors,
and are not restricted to patients who have experienced a suspected ADR. Patient records contain
a wide variety of time-stamped events that may serve as the basis for temporal pattern discovery:
drug prescriptions, laboratory test results, hospital referrals and admissions, and notes of clinical
symptoms, signs, and diagnoses (Norén et al., 2010). Long-term longitudinal capture of data in
these sources can also enable studies that monitor the performance of risk management programs or
other interventions over time (Weatherby et al., 2002).
While EHR databases provide valuable and unique opportunities for researchers to study the
risk of a large number of drugs on ADRs simultaneously, there exist limitations such as data can be
incomplete, or sometimes be artificially manipulated to serve clinical care. The principal challenge of
analyzing EHR data is the potential bias in observational studies such as confounding and selection
bias. Specifically, in the context of drug safety analyses, one of the most challenging issues is
confounding by indication, i.e., a situation in which the indication for the medical product is also
an independent risk factor for the outcome. Thus, a medical product can spuriously appear to be
associated with the outcome when no appropriate control for the underlying condition exists, and
confounding may persist despite advanced methods for adjustment (Walker, 1996; Bosco et al., 2010).
Therefore, powerful statistical methods are required to better take the advantage of the richness
of EHR data as well as overcome the downsides. Powerful statistical learning methods are able to
deal with large scaled EHR data and provide robust results. However, there are very few literatures
adapting statistical learning techniques to estimate optimal ITRs in EHR data.
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4.1.2 Statin-induced myopathy
The Indiana Network for Patient Care (INPC) includes information from five major hospital
systems (fifteen separate hospitals), the county and state public health departments, and Indiana
Medicaid and RxHub, containing health records for over 15 millions patients (Biondich and Grannis,
2004; McDonald et al., 2005). The Common Data Model (CDM) data, which is a derivation of
the INPC for this work, is to standardize the format and content of the observational data, so
standardized applications, tools and methods can be applied to them. The CDM of the INPC
contains over 60 million drug dispensing events, 140 million patient diagnoses, and 360 million
clinical observations such as laboratory results, diagnose codes, and prescription medications (Zhang
et al., 2015).
Statins, also known as HMG-CoA reductase inhibitors have been found to reduce cardiovascular
disease (CVD) and mortality in those who are at high risk (Taylor et al., 2011). They are currently
the most effective and widely prescribed drugs available for the reduction of low-density lipoprotein
cholesterol, a critical therapeutic target for primary and secondary prevention of CVD (Chatzizisis
et al., 2010). There are currently seven types of statins approved by the U.S. Food and Drug Admin-
istration (FDA), which include: Atorvastatin, Fluvastatin, Lovastatin, Pitavastatin, Pravastatin,
Rosuvastatin, and Simvastatin (Sweetman and Blake, 2011).
Side effects of statins include muscle pain, increased risk of diabetes mellitus, and abnormalities in
liver enzyme tests, among which statin-induced myopathy is a very common adverse effect. Myopathy
is a muscle disease which results in muscular weakness. In observational studies 10−15% of people
who take statins experience muscle problems, in most cases these consist of muscle pain (Abd and
Jacobson, 2011). Besides, statin-induced myopathy is likely to induce severe and potentially fatal
cases of rhabdomyolysis, a rapid destruction of skeleton muscle (Chatzizisis et al., 2010). It is
reported that Lovastatin and Pravastatin generally causes fewer side effects than others, high dose
Simvastatin may be more likely to cause muscle pain, and Rosuvastatin has the highest rates of
reported side effects. Historical data have shown that there are some certain factors to have side
effects from taking statin, such as a patient is taking more than one medication to reduce cholesterol,
is a female, is 65 years or older, or has kidney or liver disease. In this work, we consider adverse
reactions of both myopathy and rhabdomyolysis and aim to discover potential risk factors based on
available EHR data.
47
In this chapter, we apply SOM-learning to estimate optimal ITRs in EHR data collected from the
Indiana Network for Patient Care (INPC) database. The data contain basic information and medical
history of patients who have ever exposed to statin drugs. Assuming that all possible statin drugs
have equivalent efficacy, we aim to recommend personalized treatment option to each patient such
that their risks of having myopathy and rhabdomyolysis can be as low as possible, given potential
confounding factors. We first create a large set of relevant features from the medical information
provided in EHR data, and then estimate propensity scores using regularized multinomial regression.
To assure an more accurate result as well as computational capacity, we conduct repeated stratified
sampling and draw conclusions by combining estimated ITRs from all subsets. Propensity score
along with sampling proportion will be adjusted in the SOM-learning procedure.
The rest of this chapter is structured as follows. Section 2 introduces the main idea and the
mathematical framework for multicategory ITRs using SOM learning, and preparation details of
data. In Section 3, we provide results of ITR estimation using SOM-learning and compare them
with the ones using Q-learning. Conclusions and possible future works are discussed in Section 4.
4.2 Methodology
4.2.1 SOM-learning
Suppose the data contain n patients and k different treatment options. For each patient i, we
observe a d-dimensional vector of feature variables, denoted by Xi ∈ X , a treatment assignment
Ai ∈ A = {1, 2, ..., k}, i = 1, ..., n, and the clinical outcome after treatment denoted by Ri (also
referred as the “reward”), with larger values of Ri being more desirable. A multicategory ITR,
denoted by D, is a mapping from the space of feature variables, X , to the domain of treatments, A.
An optimal ITR is a treatment assignment rule that maximizes the mean reward E[R(D(X))|X],
where R(a) is the potential outcome had treatment a been given. According to Qian and Murphy
(2011), for randomized trials and assuming consistency of the potential outcomes, the optimal ITR









where πa(x) = pr(A = a|X = x) is the randomization probability for treatment a, a = 1, ..., k,,
assumed to be bounded by a positive constant from below, so
∑k
a=1 πa(x) = 1. The goal is to learn
the optimal treatment rule using empirical observations (Ri, Ai, Xi), i = 1, ..., n, and an optimal ITR
is
D∗(x) = argmaxaE[R|A = a,X = x].
One approach to estimate the optimal ITR is Q-learning, which builds a regression model to
estimate the conditional means on the right-hand side. However, it heavily relies on the correctness
of the postulated model, and model misspecification can lead to substantially non-optimal ITR even
for a binary treatment situation (Zhao et al., 2012). Alternatively, O-learning proposed by Zhao
et al. (2012) directly maximized the empirical version of the value function but replaced I(A = D(x))
by 1 −max(0, 1 − Af(x)), where f(x) is the decision function such that D(x) = sign(f(x)). The
latter corresponds to a weighted support vector machine where the weight for each observation is
proportional to Ri. They demonstrated that O-learning outperformed the regression model based
method in small sample. However, the proposed method can only be applied to estimate binary
treatment decisions, and thus not directly applicable when more than two treatment options are of
interest.
SOM-learning generalizes O-learning to fitting multi-treatment settings and transforms multi-
category ITR learning problem into a sequence of binary ones. The underlying idea is to perform a
sequence of binary treatment decision learning, where each step in the sequence determines whether
the optimal treatment for a patient should be a candidate treatment category or the other treatments.
Thus O-learning with weighted support vector machines (Zhao et al., 2012) is adapted in each
subsequent binary step with adjusted weights. The selection of weights in SOM-learning ensures
that the final rules are Fisher consistency.
Unlike randomized trials, the probability of receiving a treatment, πA(X), in observational studies
is not known at stage of study design anymore, but has to be estimated from the data. Because of the
observational nature of EHR data, we derive informative covariates from the observed measurements
to estimate the probabilities and adjust for confounding. Thus, the estimated probability (also
known as “propensity score"), π̂A(X) will replace πA(X) in the value function (4.1). Therefore, the
49








where π̂A(X) = P̂ (A = a|X = x) denote the estimated propensity score.
4.3 Data preparation
The available medical history and occurrence time of adverse reaction in the data expand from
year 2000 to 2016. Patients who experienced ADRs–myopathy or rhabdomyolysis from year 2012
to 2016 were selected as cases, and those didn’t experience any ADRs during 2012 to 2016 served
as controls. The ADR was then scored as 10, 1, and 0 for rhabdomyolysis, myopathy or control,
respectively. The outcome value of interest is the number of ADR occurrences multiplies the score
of ADR during year 2012 to 2016. Demographic variables include age at 2012 and gender. There are
a total of 270,118 patients in the dataset.
The data contain information of more than 1000 drugs, among which we excluded very rarely
used ones cutting at the 5th percentile of frequencies and 187 drugs left for further analysis. There
are five different statin medicines among all the 187 drugs: Lovastatin, Pravastatin, Simvastatin,
Atorvastatin, and Rosuvastatin. Based on the marketing popularity and potency ranking, we combine
Lovastatin and Pravastatin into one group. Thus, there are 4 possible treatment options in this
problem. Table 4.1 summarizes number of patients who have mostly exposed to each drug.
Table 4.1: Information of Statins
Group Statin Medicine Number of Patients
Statin 1 Lovastatin & Pravastatin 45,912
Statin 2 Simvastatin 196,657
Statin 3 Atorvastatin 17,604
Statin 4 Rosuvastatin 9,945
Total 270,118
For the remaining 182 drugs, we computed the duration and frequency for each drug use and
adjusted them by the length of patients’ drug record history during 2000-2012. We also included the
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rate of ADR occurrence. Therefore, for each patient, 364 drug related variables, in addition with age
at 2012, gender, and previous rate of ADRs were included in further analyses.
Regularized multinomial regression was carried out to estimate propensity scores for each patient
with outcome being the 4 statin treatment options. The optimal tuning parameter for LASSO
penalty in the regression model is chosen by cross validation. The model also selected 322 out of the
367 feature variables, among which age, gender and previous case rate were all kept.
4.3.1 Clustering of variables
Due to the sparsity of feature variables, we conducted clustering to group them into homogeneous
clusters and reduce dimension using R package ClustOfVar (Chavent et al., 2011). This algorithm is
to find a partition of a set of variables such that the variables within a cluster are related to each
other as strongly as possible.
According to Chavent et al. (2011), a synthetic variable ck of a cluster Ck is defined as the
variable “most linked" to all variables in Ck based on their Pearson correlation. Let Xk denote the
matrix of Ck, extracting from our data matrix X. Specifically, ck is the first principal component of
Xk. Finally, 20 synthetic variables from 20 clusters, age and gender were selected to learn optimal
ITRs.
4.3.2 Stratified sampling and SOM-learning
One main concern raised by the richness of EHR data is that it requires high computational
capacity. To lighten the burden of computation for SOM learning and make sure there are enough
ADRs being selected, we conducted stratified simple random sampling. There were 14 strata which
were formed based on patients categorized age and gender. Because there are much more controls
than cases, in each stratum we kept all cases and randomly selected the same number of controls.
These subsets of the strata are then pooled to form a random sample.
Let ph(x) denote the probability of a patient being selected from its strata h, where h = 1, ..., 14.
From our setting of stratified sampling, ph(x) = 1 for cases and ph(x) = nh(case)/nh(control) for
controls, where nh(case), nh(control) denote the original number of cases and controls in the stratum.
The sample size of each stratum and the probability of a control being selected are summarized in
Table 4.2.
Then we used the selected sample to train SOM-learning rules. Within each step of SVMs in
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SOM-learning, the inverse of ph(x) were multiplied to the inverse of propensity scores as weights
after being truncated at the 99th percentile. To control for sampling bias, we repeated stratified
sampling and computed expected outcome values for the whole data using the rules learned from
different samples.
Table 4.2: Sample sizes of each stratum
Female, Age <= 40 41− 50 51− 60 61− 70 71− 80 > 80
Number of cases 1005 2438 4014 3297 1967 1593
Pr(control) 0.15 0.16 0.13 0.09 0.08 0.09
Male, Age <= 40 41− 50 51− 60 61− 70 71− 80 > 80
Number of cases 346 981 1577 1309 855 504
Pr(control)1 0.05 0.05 0.05 0.04 0.05 0.05
1 The probability of a control being selected.
4.4 Analysis of confounding
In addition to the preparation steps listed above, we also did confounding analysis and model
selection based on several parametric approaches.
A confounding variable is the one influences both treatment and outcome. To determine the
potential confounder, we first computed the Spearman’s correlations of the 322 variables with
treatment indicators and outcome. Because of the large sample size, 0.05 is not a suitable threshold
of significance. A correlation with absolute value below 0.01 can have a p-value< .0001. Thus, we
selected confounding variables for which the absolute value of the correlation with outcome and at
least one of the treatment indicators was greater than 0.02. There were 33 variables met the criteria,
which included age, gender, historical case rate and 30 drug related variables.
Next, we tried to select the variables that are predictable to outcome. Because of the fact that
92.6% of outcome value is 0, we applied a continuous odds ratio model with categorized outcome.
The outcome y was categorized at 4 thresholds: 1, 4, 8, and 16. We created three subsets from the
original dataset which contained patients with outcome greater than 1, 4 and 8, respectively. The
sample sizes of the subsets were 19813, 8556, and 5311. A new dichotomous response v was defined
based on the following rules. We stacked the four datasets and built a logistic regression model
with v as the dependent variable and the 33 variables as covariates and forward selection method
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was applied. Furthermore, drug information was dichotomized to used or not. After all, gender,
case rate, and 5 medication use (Pregabalin, Acetaminophen, Loratadine, Acetylsalicylic acid, and
Gabapentin) were selected. These drugs are all related to muscle weakness or pain. Last, we regress
on the dichotomous response v using the selected 7 variables and treatment as covariates for the
original dataset.
Definition of response v:
Original dataset: v = 1 if y >= 1, v = 0 if y = 0;
Subset 1: v = 1 if y >= 4, v = 0 otherwise ;
Subset 2: v = 1 if y >= 8, v = 0 otherwise ;
Subset 3: v = 1 if y >= 16, v = 0 otherwise .
4.5 Results
4.5.1 Descriptive statistics
Among all the 270,118 patients, there were 250,234 (92.6%) controls, 18,701 (7.0%) were with
myopathy cases and 1,183 (0.4%) were rhabdomyolysis cases. There are 144,819 (54%) females
and 125,301 (46%) males. 224,587 (83%) patients had 0 case occurrence from 2000 to 2012. More
descriptive statistics by statin groups are summarized in Table 4.3. Moreover, the association
between value, case rate and statin groups are both statistically significant (P < .0001). Figure 4.1
shows the histograms of patients’ age at 2012. From the histogram of estimated propensity scores
(see Figure 4.2), we can tell that the probability of a patient being assigned to a statin medicine is
not completely at random and most of the patients were assigned to their treatment with probability
about 0.75.
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Table 4.3: Descriptive statistics
Variable Statistic Statin 1 Statin 2 Statin 3 Statin 4 Total
Outcome mean (sd) 0.6213 (5.0419) 0.6524 (5.6157) 0.9894 (6.5368) 0.8179 (5.7632) 0.6752 (5.5942)
(min, max) (0, 320) (0, 640) (0, 470) (0, 250) (0, 640)
Case rate mean (sd) 0.0178 (0.1281) 0.0204 (0.1427) 0.0284 (0.0642) 0.0223 (0.0564) 0.0205 (0.1342)
(min, max) (0, 22) (0, 24) (0, 0.825) (0,0.812) (0, 24)
Control n 42,590 182,836 15,742 9,066 250,234
Myopathy n 3,141 12,974 1,766 820 18,701
Rhabdomyolysis n 181 847 96 59 1,183
Figure 4.1: Histogram of age at 2012.
Figure 4.2: Histogram of estimated propensity scores.
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4.5.2 Predicted ITR
To compare the results of SOM-learning, we also conducted random forest based Q-learning
using age, gender, 20 synthetic variables from clustering, and their interactions with statin groups as
feature variables. The original number of patients in each treatment group is 45912, 196657, 17604,
and 9945, respectively. Table 4.4 gives the outcome value of “one-size-fits-all" method. Results of
SOM-learning from 10 stratified samples are summarized in Table 4.5. Results of Q-learning using
the same samples are provided in Table 4.6 for reference.
We see that Q-learning recommended Lovastatin or Pravastatin to majority of patients and
gained a smaller predicted value compared to the “one-size-fits-all" method. However, since the
training data is a subsample of test data, random forest based Q-learning may lead to overfitting.
Thus, we are not able to conclude that the optimal ITRs obtained by random forest based Q-learning
are superior than non-individualized treatment rules. The results for SOM-learning from different
samples are fairly consistent. The estimated ITRs are more likely to allocate patients to Simvastatin
and very few to Atorvastatin or Pravastatin. The predicted outcome value from SOM-learning is a
little bit larger than the value of Simvastatin in “one-size-fits-all" rule.
Table 4.4: Outcome of “one-size-fits-all" (a smaller value indicates a better outcome)
Statin 1 Statin 2 Statin 3 Statin 4
0.6495 0.6570 0.8197 0.7470
Table 4.5: Summary of predicted labels and outcome values from different samples of SOM-learning
(a smaller value indicates a better outcome)
Statin 1 Statin 2 Statin 3 Statin 4 Value
Sample 1 3857 265187 857 217 0.6580
Sample 2 1174 268398 350 196 0.6633
Sample 3 4145 264215 1556 202 0.6625
Sample 4 11169 254231 4318 400 0.6657
Sample 5 5963 261947 1267 941 0.6670
Sample 6 1864 267648 359 247 0.6652
Sample 7 1153 268468 277 220 0.6634
Sample 8 5673 262824 622 999 0.6640
Sample 9 8569 256798 4446 305 0.6607
Sample 10 6040 262996 848 234 0.6652
Std deviation 3241.23 4745.35 1577.83 308.77 0.0026
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Table 4.6: Summary of predicted labels and outcome values from different samples of Q-learning (a
smaller value indicates a better outcome)
Statin 1 Statin 2 Statin 3 Statin 4 Value
Sample 1 171573 97892 440 213 0.2465
Sample 2 175661 93928 405 124 0.2420
Sample 3 176694 92768 476 180 0.2394
Sample 4 176476 93036 470 136 0.2404
Sample 5 177513 92010 349 246 0.2426
Sample 6 174723 94731 300 364 0.2465
Sample 7 172543 97169 288 118 0.2386
Sample 8 173597 95962 399 160 0.2447
Sample 9 173906 95726 350 136 0.2444
Sample 10 173589 95868 446 215 0.2411
Std deviation 1927.20 1949.13 67.88 75.23 0.0028
4.5.3 Confounding analysis
The estimated odds ratio with 95% confidence interval (CI) of the logistic regression model
introduced in section 4.4 are summarized in Table 4.7. We can see that Lovastatin or Pravastatin is
significantly associated with a severer outcome compared to Simvastatin. Female is more likely to
end up with myopathy or rhabdomyolysis after taking statin medicines.
Table 4.7: Summary of odds ratio estimates
Variable Odds Ratio 95% CI p-value
Female 1.304 (1.251, 1.358) < .0001
Statin 1 vs 2 1.092 (1.037, 1.151) 0.0008
Statin 3 vs 2 0.994 (0.931, 1.061) 0.8564
Statin 4 vs 2 1.010 (0.921, 1.108) 0.8248
Drug 11 1.494 (1.411, 1.581) < .0001
Durg 2 0.853 (0.805, 0.904) < .0001
Drug 3 1.111 (1.062, 1.163) < .0001
Drug 4 0.984 (0.943, 1.027 0.4616
Drug 5 1.151 (1.104, 1.200) < .0001
1 Drug 1-5 are Pregabalin, Acetaminophen, Loratadine,
Acetylsalicylic acid, and Gabapentin, respectively.
4.6 Discussion
We have applied the proposed SOM-learning method to estimate the optimal ITRs for EHR
data by solving a multicategory treatment selection problem via sequential weighted support vector
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machines. We considered statin-induced myopathy and rhabdomyolysis as ADRs and tried to learn
the optimal ITRs with minimum average scores of such ADRs. The treatment choice recommended
by Q-learning was more desirable compared to the non-individualized “one-size-fits-all" rules. For
SOM-learning, we applied sampling technique and inverse probability weighting scheme to assure
the computational capability. However, due to the observational nature of this dataset and potential
bias caused by sampling, the results of SOM-learning is not as expected. Therefore, one possible
approach to improve the performance of SOM-learning is to develop more efficient function with
parallel computing such that it is able to handle high-dimensional data as is in this case.
Machine learning methods are powerful in analyzing high-dimensional and sparse data from
EHR databases as is showed in this work. Tailored by patients’ characteristics and medical histories,
the estimated ITRs are able to recommend treatment with lower risk of having ADRs induced
by medicines. Because of the observational feature of EHR data, inverse probability weighting
of propensity score was adopted to adjust for bias of observed features. However, unobserved
confounding and bias may still exist thus require more attention for ITRs that are estimated from
non-experimental studies.
One limitation of this work is the definition of outcome and features. Especially for the outcome,
we took score 0, 1, and 10 for different levels of ADR severity. However, these scores may not be
clinically meaningful, and because it’s critical to results, a misleading definition may end up with
incorrect estimation of ITRs. A more rational definition of the ADR outcome is needed. Another
possibly problematic part is the estimation of propensity scores. As shown in Figure 4.2, there are
two obvious clusters for the estimated propensity scores, which is an unusual situation. Directly
adopting these propensity scores may lead to mis-estimated value functions. An alternative approach
is to split all the patients into two groups based on their propensity scores and redo the analysis
separately for the two groups. Because the estimated propensity scores are distributed roughly
normally in each of the two clusters (see Figure 4.2), this approach may help to improve the final
decision of optimal treatment rules.
While statin-induced myopathy has been shown to be dose dependent (Pasternak et al., 2002),
one potential extension of our work is to make use of the information of drug dose and choose more
accurate and effective treatment for patients. Other risk factors, for instance, history of disease such
as hypertension, hypercholesterolemia and diabetes, alcohol abuse, ethnicity, and are worth exploring
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when available (Golomb and Evans, 2008). Additionally, on the basis of temporal information, we
could search for a different baseline other than 2012 to make more practical sense and make fully use
of the time information. Moreover, for diseases with multiple-stage therapy, powerful methodologies
of estimating dynamic treatment regimes (DTRs) are explored to obtain favorable outcomes (Murphy,
2003; Robins, 2004; Moodie et al., 2007; Zhao et al., 2011; Zhang et al., 2012, 2013; Liu et al., 2014).
In this work, we have focused on single-stage medical decision making, the proposed procedure can
be easily generalized to handle multicategory DTRs for multiple-stage trials. Except for machine
learning techniques we have focused on, parametric approaches can be helpful in analyzing this type
of data. For example, logistic regression models with dichotomized or categorized outcome are useful
to detect the prediction performance of interesting covariates and a model selection method can help
with dimension reduction when there is a large amount of covariates.
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CHAPTER 5: CONCLUSIONS AND FUTURE DIRECTIONS
This dissertation focused on developing new and computationally efficient statistical learning
methods and algorithms for multicategory classification and multicategory personalized medical
decision making. We are motivated by two goals: create consistent rules for multicategory classifi-
cation problems, and develop computationally efficient algorithms based on binary support vector
machines (SVM). We first proposed forward-backward SVM method to consistently and efficiently
learn multicategory rules for classification. The learning algorithm was then adapted to estimating
multicategory individualized treatment rules via a connection with outcome weighted learning
proposed by Zhao et al. (2012). In this work, we established theoretical properties for the proposed
method such as Fisher consistency and risk bound of the derived learning rules. In addition, we
showed that our methods performed promisingly in both extensive simulation studies and real-world
data analysis, with low misclassification rates and significantly improved computational speed when
compared to existing methods. Nevertheless, some potential improvements and extensions of this
work merit future exploration.
First of all, while a major computational cost for the proposed learning algorithms is to screen
all possible permutations of the categories, their computational performance can be immediately
improved. Because the sequential learning for each permutation can be carried out independently of
one another, we can incorporate distributed computing to leverage this natural parallel computing
structure (Almasi and Gottlieb, 1988). This improvement is worth pursuing especially for the
applications with a large number of categories. Another approach is to explore a more efficient and
effective methodology for a data-driven choice of tuning parameter in the loss functions. These
potential improvements could end up with a more sophisticated computational software or package.
Second, although our algorithm was originally developed based on SVMs, other binary classifiers
can be easily implemented and applied alternatively. In each binary step, we can replace SVM with
other large-margin classifiers, such as adaboost (Freund and Schapire, 1997), import vector machines
(Zhu and Hastie, 2005), ψ-learning (Shen et al., 2003), and large-margin unified machines (Liu
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et al., 2011). The multicategory rules derived from the proposed algorithm will remain consistent
as long as the input binary classifiers are consistent. Moreover, we compared the performance
of our method only with other multicategory classification methods of SVMs. Indeed, it may be
more critical if we expand the comparisons to other methods who deal with categorical outcomes,
such as parametric models like multinomial regression, or other machine learning approaches like
random forests (Ho, 1995, 1998), and neural networks (Specht, 1990; Khan et al., 2001) etc. Another
possible improvement of our algorithm is to develop a build-in function to handle missing data when
analyzing real data.
Third, we suggested to treat the most prevalent category as the first target in the sequences
of learning procedure, however, this may result in few cases for later categories in consideration
and cause a large misclassification rate for subjects whose optimal categories are less prevalent.
In practice, when different categories have different importance, for instance, multiple treatment
options with the need to balance efficacy and risk, the order of the targeted categories should take
the practical importance into account. This arises another possible extension that we can broaden
our method to resolve classification problems with ordinal categories.
Furthermore, for some chronic diseases with multi-stage therapy, dynamic treatment regimes
(DTRs) can be more powerful in obtaining favorable outcomes than a simple combination of single-
stage treatment rules. Various approaches have been developed to estimate optimal DTRs, such as
Murphy (2003); Robins (2004); Moodie et al. (2007); Zhao et al. (2011); Zhang et al. (2012, 2013);
Liu et al. (2014). While our method focused on single-stage studies only, the proposed procedure
can be easily generalized to handle multicategory DTRs for multiple stage trials.
Finally, statistical analysis for observational data can be extremely challenging, especially for the
large scale data collected from EHR database. Different from intervention studies, subjects in these
databases are rarely assigned to randomized treatment groups. Instead, they receive treatments
based on the known characteristics, medical history and onset symptoms. Propensity scores methods
(Rosenbaum and Rubin, 1983) such as matching, stratification and inverse probability weighting are
mostly widely used to adjust for potential confounding and bias when making inference of causality.
More effective and accurate approaches for matching and weighting are desirable. Recently, in
drug developing industry, there is an increasing interest of comparing different drugs from different
data sources with various inclusive criteria. Thus, matching techniques are worth exploring not
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only for observational studies, but also for clinical trials. Besides, people could combine parametric
methods and machine learning to seek for more reasonable and reliable results when analyzing big
observational data from EHR databases.
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APPENDIX
A.1 Proof of Theorem 2.1
We start from class label k and follow the order in FB-SVM. First, we show D∗(X) = k if and
only if Pk(X) = maxkh=1 Ph(X). For any X with D∗(X) = k, by the definition of D∗, there exists a
permutation (j1, ..., jk−1) of {1, ..., k − 1} such that D
∗(k)
l (X) = −1 for l = j1, ..., jk−1. That is,
f∗j1(X) < 0, f
∗
j2(X) < 0, . . . , f
∗
jk−1
(X) < 0. (1)
On the other hand, from the estimation of f̂j1 , it is clear that f∗j1 is the minimizer of the expectation





I(Y = j1)[1− f(X)]+ +
1
k









(1− Pj1(X))[1 + f(X)]+
]
.
Simple algebra following standard SVM theory gives







That is, f∗j1(X) < 0 is equivalent to Pj1(X) < 1/k. Now, in the next step, because we restrict to








I(Y = j2)[1− f(X)]+ +
1
k − 1







{Pj2(X)(k − 2)[1− f(X)]+
+(1− Pj1(X)− Pj2(X))[1 + f(Xi)]+}
∣∣∣Pj1(X) < 1/k] .
Thus, we conclude that
sign(f∗j2(X)) = sign (Pj2(X)(k − 2)− (1− Pj1(X)− Pj2(X)))× I{Pj1(X) < 1/k}.
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k − l + 1
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.
In other words, we obtain that for this subject with f∗j1(X) < 0, ..., f
∗
jk−1










, · · · , (2)
Pjk−2(X)











Starting from the last inequality, we have
Pjk−1(X) < Pk(X), Pjk−2(X) <
1
3
(Pjk−2(X) + Pjk−1(X) + Pjk(X)),












Therefore, Pk(X) = maxkl=1 Pl(X).
For the other direction, suppose that Pk(X) = maxkl=1 Pl(X). We order P1(X), ..., Pk−1(X)
to obtain a sequence with Pj1(X) ≤ Pj2(X) ≤ · · · ≤ Pj(k−1)(X) ≤ Pjk(X). We consider the
corresponding classification rules for the same sequence. Because all inequalities in (4) and (5) hold,
from the equivalence between f∗jl and Pjl , it is straightforward to see that




In other words, D∗(X) = k. Hence, we have proved that the FB-SVM rule is the Bayesian rule that
correctly classifies subjects into class k .
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To prove the consistency of the remaining classes, FB-SVM obtains the rule for class (k − 1)
conditional on Y 6= k and D∗(X) 6= k. Using the same proof as above, we conclude that
D∗(X) = (k − 1) if and only if (k − 1) = argmaxk−1l=1 P̃k−1,l(X),
where P̃k−1,l(X) is the conditional probability of Y = l given X = X, Y 6= k, and D∗(X) 6= k.
Clearly, P̃k−1,l(X) is proportional to Pl(X) for l = 1, ..., k − 1. Moreover, D∗(X) 6= k implies that
Pk(X) cannot be the maximum. Therefore,




D∗(X) = (k − 1) if and only if (k − 1) = argmaxkl=1Pl(X).
We continue this proof for the remaining classes and finally obtain Theorem 2.1.
A.2 Proof of Theorem 2.2
We first examine the difference
∆k = P (Y = k, D̂(X) 6= k)− P (Y = k,D∗(X) 6= k).
Clearly,
∆k ≤ P (Y = k, D̂(X) 6= k,D∗(X) = k).
From Theorem 1, for any x in the domain of X, we let j1(x), j2(x), ..., jk−1(x) be the permutation
of {1, ..., k − 1} such that
P (Y = j1(x)|X = x) < ... < P (Y = jk−1(x)|X = x).
Then, D∗(x) = k implies that f∗jl(x)(x) < 0 for any l = 1, .., k − 1. On the other hand, D̂(X) 6= k




































Hence, it suffices to bound each term on the right-hand side of the above inequality.
When l = 1, under conditions (2.1)-(2.4), from Theorem 8.25 in Steinwart and Christmann
(2008), there exists a probability at least 1− 3e−ε and a constant C1 such that





















with any constant ε0 > 0 and d/(d+ τ) < p < 2. According to Lemma 5 in Bartlett et al. (2006)
and condition (2.2), this gives
P (f̂j1(X)f
∗
j1(X) < 0) ≤ [C1Qn(ε)]
α,
where α = q/(1 + q).
When l = 2, because Zij2 is no longer defined if Zij1 = 1, we extend to define Zij2 = 1 if Zij1 = 1.




I(Zij1 f̂j1(Xi) > 0)(1− Zij2g(Zij1 ,Xi))+ + λn(‖g(1,x)‖+ ‖g(−1,x)‖),










I(Zij1 = −1, f̂j1(Xi) < 0)(1− Zij2g(−1,Xi))+ + λn‖g(−1,x)‖.
Thus, it is obvious that the optimal estimator for g, denoted by ĝ, is given as
ĝ(1,x) = 1, ĝ(−1,x) = f̂j2(x).
Similarly, the optimal estimator that minimizes the limit is given as
g∗(1,x) = 1, g∗(−1,x) = f∗j2(x).
We then apply to ĝ the same arguments used by Steinwart and Christmann (2008) to prove Theorem
8.25 and obtain
P (Zj2 ĝ(Zj1 ,X) < 0)− P (Zj2g∗(Zj1 ,X) < 0)
≤ C2
{
Qn(ε) + |P (Zj1 f̂j1(X) > 0)− P (Zj1f∗j1(X) > 0)|
}
with a probability at least 1− 3e−ε for a constant C2. The second term in the right-hand side is due
to that the estimation is conditional on a random set with Zij1 f̂j1(Xi) > 0. On the other hand, from
the previous result at l = 1, this term is bounded by C1Qn(ε) with probability at least 1− 3e−ε. We
conclude that with a probability at least 1− 6e−ε, it holds that
P (Zj2 ĝ(Zj1 ,X) < 0)− P (Zj2g∗(Zj1 ,X) < 0) ≤ C3Qn(ε)
for C3 = C2(1 + C1). From the fact that ĝ = g∗ = 1 if Zj1 = 1, we have that with a probability at
least 1− 3e−ε,
P (Zj1 = −1, Zj2 f̂j2(X) < 0)− P (Zj1 = −1, Zj2f∗j2(X) < 0)
≤ C3Qn(ε).
Thus, Lemma 5 in Bartlett et al. (2006) gives
P (Zj1 = −1, f̂j2(X)f∗j2(X) < 0) ≤ [C3Qn(ε)]
α.
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(X) < 0, Zjl−1 = −1, ..., Zj1 = −1
}]
≤ ClQn(ε)
with a probability at least 1− 3le−ε. Hence, with a probability 1− [3k(k − 1)/2]e−ε, ∆k ≤ CQn(ε)α
for a constant C.
Similarly, we can examine the difference
∆k−1 = P (Y = k − 1, D̂(X) 6= k − 1)− P (Y = k − 1,D∗(X) 6= k − 1).
We follow exactly the same arguments as before by considering all possible permutations from
{1, ..., k − 2} and l = 1, ..., k − 2. The only difference in the argument is that the random set
is restricted to subjects with Yi 6= k and D̂(k) = −1. However, the probability of the latter
differs from the probability Yi 6= k and D∗(k) = −1 by CQn(ε) from the previous conclusion.
Therefore, we obtain that with a probability at least 1 − [3k(k − 1)/2 + 3(k − 1)(k − 2)/2]e−ε,
∆k−1 ≤ CQn(ε)α for another constant C. Continue the same arguments for ∆l, l = k − 2, ..., 1,
where ∆l = P (Y = l, D̂(X) 6= l)− P (Y = l,D∗(X) 6= l). Finally, by combining all these results, we
conclude that
P (Y 6= D̂(X)) ≤ P (Y 6= D∗(X)) + CQn(ε)α
with a probability at least 1− C ′e−ε, where C ′ is a constant depending on k. Theorem 2.1 holds.
A.3 Proof of Theorem 3.1
We start from class label k following the order in SOM. First, we show D∗(x) = k if and
only if E(R|X = x,A = k) = maxkl=1E(R|X = x,A = l). For any x with D∗(x) = k, by the
definition of D∗, there exists a permutation (j1, ..., jk−1) of {1, ..., k − 1} such that D
∗(k)
l (x) = −1
for l = j1, ..., jk−1. That is,
f∗j1(x) < 0, f
∗




where f∗jl is the counterpart of f̂j1 when n =∞.
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On the other hand, from the estimation of f̂j1 , it is clear that f∗j1 is the minimizer of the

























































∣∣∣∣X = x,A = jl) {1 + f(X)}+ + E ( k − 1k R−
∣∣∣∣X = x,A = j1) {1 + f(X)}+
where R+ = RI(R > 0), R− = −RI(R ≤ 0), and R = R+ −R−.













∣∣∣∣X = x,A = jl)
}
{−f(X)}+ constant (4)
It’s clear that we cannot find a minimizer for (1). Similarly, the minimizer cannot be in the
interval f(x) ∈ [1,∞). Therefore, we only consider f(X) ∈ (−1, 1). Then the expectation of a




















∣∣∣∣X = x,A = jl) {1 + f(X)}+ + E ( k − 1k R−









∣∣∣∣X = x,A = jl)− E ( k − 1k R
∣∣∣∣X = x,A = j1)
}
f(X) + constant












∣∣∣∣X = x,A = jl) ,
which is equivalent to
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E (R|X = x,A = jl) .










I(A = j2){1− f(X)}









I(A = jl){1− f(X)}










I(A = jl){1 + f(X)}
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∣∣∣∣X = x,A = jl, f∗j1(X) < 0}− E{ k − 2k − 1R




Thus, we conclude that
sign{f∗j2(X)} =sign[E{(k − 2)R|X = x,A = j2} −
k∑
l=3
E{R|X = x,A = jl}]I{f∗j1(X) < 0}.
That is, f∗j2(x) < 0 if and only if





E(R|X = x,A = jl)










E(R|X = x,A = jh)
}
In other words, we obtain that for this subject with f∗j1(x) < 0, ..., f
∗
jk−1
(x) < 0, it holds





E(R|X = x,A = jl),





E(R|X = x,A = jl),
...
E(R|X = x,A = jk−2) < 1/2{E(R|X = x,A = jk−1) + E(R|X = x,A = k)},
E(R|X = x,A = jk−1) < E(R|X = x,A = k).
Starting from the last inequality in the above, in turn, we have
E(R|X = x,A = jk−1) < E(R|X = x,A = k)
E(R|X = x,A = jk−2) < 1/2{E(R|X = x,A = jk−1) + E(R|X = x,A = k)}
< E(R|X = x,A = k),
...





E(R|X = x,A = j1) < E(R|X = x,A = k).
Therefore,
E(R|X = x,A = k) = kmax
l=1
E(R|X = x,A = l).
For the other direction, we suppose that
E(R|X = x,A = k) = kmax
l=1
E(R|X = x,A = l).
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We order the expectations to obtain
E(R|X = x,A = j1) ≤ E(R|X = x,A = j2) ≤ ... ≤ E(R|X = x,A = k)
Thus all the inequalities in (2)-(7) hold, from equivalence between f∗jl and E(R|X = x,A = jl)’s, it
is straightforward to see that




In other words, D∗(x) = k. Hence, we have proved that SOM learning correctly assigns subjects
whose conditional mean outcomes are maximal in treatment k into the optimal treatment k.
To prove the consistency of the remaining classes, obtains the rule for class (k − 1) conditional
on A 6= k and D∗(X) 6= k. Using the same proof as above, we conclude
D∗(x) = (k − 1) if and only if (k − 1) = argmaxk−1l=1 Ẽ(R|X = x,A = l),
where Ẽ(R|X = x,A = jl) is the conditional expectation of R given X = x, A 6= k and D∗(X) 6= k.
Moreover, D∗(x) 6= k implies that E(R|X = x,A = k) cannot be the maximum. Therefore,
(k − 1) = argmaxk−1l=1 E(R|X = x,A = l) = argmax
k
l=1E(R|X = x,A = l).
That is,
D∗(x) = (k − 1) if and only if (k − 1) = argmaxkl=1E(R|X = x,A = l).
We continue this proof for the remaining classes and finally obtain Fisher consistency.






































































I(A 6= l, D̂(X) 6= l,D∗(X) = l)
}]

















I(Zlsign(R) = 1, D̂(X) 6= l,D∗(X) = l)
}
,
where we recall Zl = 2I(A = l)− 1.
We first examine ∆k. For any x in the domain of X, we let j1, j2, ..., jk−1 be the permutation of
{1, ..., k − 1} such that
E(R|A = j1, X = x) < ... < E(R|A = jk−1, X = x).
Then according to SOM learning, D∗(x) = k implies that f∗jl(x)(x) < 0 for any l = 1, .., k − 1, while
D̂(X) 6= k implies that for this particular permutation, there exists some l = 1, ..., k − 1 such that
f̂jl(x) > 0 so f̂jl(x)f
∗
jl
(x) < 0. Recall that f∗jl(x) = ηjl,S with S = {jl+1, ..., k} and it is the limit of

































{I(A = jl)(k − l + 1) + I(A 6= jl)}
×I
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Hence, it suffices to bound each term on the right-hand side of the above inequality.
When l = 1, under conditions 3.1-3.3, we use the same proof of Theorem 3.2 in Zhao et al. (2012),
which extends the result in Steinwart and Christmann (2008) to a weighted support vector machine.
Particularly, in their proof, we let the weight for subject i be
|Ri|/πAi(Xi) {(k − 1)I(Ai = j1) + I(Ai 6= j1)}
and the class label be Zj1sign(Ri). Furthermore, from the proof of Theorem 3.1, f∗j1(x) has the same
sign as ηj1,{j2,...,jk}(x). Thus, from condition (3.1), we conclude that there exists at least probability


































with any constant ε0 > 0 and d/(d+ τ) < p < 2. Then according to the proof of Lemma 5 in Barlette
et al. (2006) and conditions 3.1 and 3.2, this gives
pr{f̂j1(X)f∗j1(X) < 0} ≤ {C
′
1Qn(ε)}α,
where α = q/(1 + q) and C ′1 is a constant.




I{Zij1 = −1, Zij1sign(Ri)f̂j1(Xi) < 0}wi{1− Zij2sign(Ri)f(Xi)}+ + λn,j2‖f‖2,
where wi = |Ri|/πAi(Xi) {(k − 2)I(Ai = j2) + I(Ai 6= j2)} . Thus, we can proceed the same proof of
Theorem 3.2 in Zhao et al. (2012) except that only subjects in the random set
{
i : Zij1 = −1, Zij1sign(Ri)f̂j1(Xi) < 0
}
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Qn(ε) + |pr(Zj1sign(R)f̂j1(X) > 0)− pr(Zj1sign(R)f∗j1(X) > 0)|
}
≤ C2 {Qn(ε) +Qn(ε)α}
with a probability at least 1− 3e−ε for a constant C2. Note that the second term on the right-hand
side is due to the estimated random set in this step. Again, the proof of Lemma 5 in Barlette et al.
(2006) gives
pr{Zj1 = −1, f̂j2(X)f∗j2(X) < 0} ≤ {C
′
2Qn(ε)}α.





{(k − l + 1)I(A = jl) + I(A 6= jl)}
× I
{












(X) < 0, Zjl−1 = −1, ..., Zj1 = −1
}]
≤Cl {Qn(ε) +Qn(ε)α}
with a probability at least 1− 3le−ε for some constant Cl, and
pr{Zj1 = −1, ..., Zjl−1 = −1, f̂jl(X)f
∗
jl
(X) < 0} ≤ {C ′lQn(ε)}α
for a constant C ′l . Hence, with a probability 1− {3k(k − 1)/2}e−ε, ∆k ≤ CQn(ε)α for a constant C.
Similarly, we can examine the difference for ∆k−1. We follow exactly the same arguments
as before by considering all possible permutations from {1, ..., k − 2} and l = 1, ..., k − 2. The
only difference in the argument is that the random set is restricted to subjects with A 6= k and
D̂(k)(X) = −1. However, the probability of the latter differs from the probability A 6= k and
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D∗(k)(X) = −1 by CQn(ε)α from the previous conclusion. Therefore, we obtain that with probability
at least 1−{3k(k−1)/2+3(k−1)(k−2)/2}e−ε, ∆k−1 ≤ CQn(ε)α for another constant C. Continue
the same arguments for ∆l, l = k − 2, ..., 1 so we finally conclude
R(D̂)−R∗ ≤ CQn(ε)α
with probability at least 1− C ′e−ε where C ′ is a constant depending on k. Thus Theorem 3.2 holds.
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